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Over the last decade attempts at reducing morbidity and mortality of patients with 
chronic heart failure have been made via the development and implementation of novel 
cell based therapies. Substantial advances in cell based therapies with indications of 
efficacy have been shown along with a robust safety profile.  Despite these advances, 
there is a substantial unmet need for novel therapies, specifically addressing repair and 
regeneration of the damaged or lost myocardium and its vasculature. Accordingly, 
cardiac cell-based therapies have gained attention. Various cell-types have been utilized, 
including bone marrow-derived mononuclear cells, bone marrow-derived mesenchymal 
stem cells, mobilized CD34+ cells, and more recently, cardiosphere-derived cells and 
cardiac-derived c-kit positive progenitor cells. Early studies have suggested a potential of 
cell-based therapies to reduce cardiac scar size and to improve cardiac function in 
patients with ischemic cardiomyopathy. However, variability of results has been observed 
necessitating improvement of current methodologies related to 
vii 
 
optimizing the cell type(s), infusion techniques, timing, dosage, acuity related to ischemic 
injury, and perhaps repeat dosing over time among others, all the while ensuring 
complete and total patient safety. Accordingly, present efforts and goals of my research 
are aimed at i.) Optimizing methodologies utilized within the recent phase I clinical trial 
(SCIPIO) that showed intracoronary infusion of 1 million c-kit positive cardiac 
progenitor cells was safe with indications of efficacy in cardiac repair, as well as, ii.) 
Development of a novel cell based approach with a newly discovered cardiac cell type. 
Within the present dissertation, I explored the impact of coronary stop-flow on 
cardiac retention of intracoronarily infused c-kit positive cardiac progenitor cells given 
that balloon inflation in a non-stented coronary artery is inherently dangerous, especially 
in already damaged hearts.  I demonstrate that intracardiac retention with or without stop-
flow is equivalent and balloon inflation confers an undue risk to patients.  Furthermore, I 
investigated the safety of intracoronary infusion of 20 million c-kit positive cardiac 
progenitor cells in pigs, an equivalent dose 40 times larger than was used in the SCIPIO 
trial. High dose of cells delivered intracoronarily is safe and does not result in myocardial 
injury or functional deficit. Therefore, larger doses may reasonably be utilized in future 
clinical trials.  Finally, I describe a novel adult cardiac cell type that maintains expression 
of an embryonic stem cell associated marker, stage-specific embryonic antigen (SSEA)-3, 
resides within the native adult heart, and can be isolated and utilized for cardiac repair as 














LIST OF FIGURES…………………………………………………………………… x 





I: CELL BASED THERAPIES FOR CARDIAC REPAIR 1 
   
Introduction…………………………………………………………… 1 
   
Review of approaches in cell therapy for myocardial repair…………. 3 
 
Non-cardiac cells utilized for cell therapy……………………. 3 
  
   Intrinsic cardiac cell types utilized for cardiac repair ………...17 
 
  C-kit positive cardiac progenitor cells…………………………………24 
            
Dissertation Overview………………………………………………… 28 
 
Hypothesis and Research Aims……………………………………….. 29 
 
II: EFFECT OF THE STOP-FLOW TECHNIQUE ON CARDIAC RETENTION  
OF C-KIT POSITIVE HUMAN CARDIAC PROGENITOR CELLS AFTER  
INTRACORONARY INFUSION IN A PORCINE MODEL OF CHRONIC  
ISCHEMIC CARDIOMYOPATHY         




Design and Methods………………………..………………………… 34 
   
Results………………………………………………………………….41 
   
Discussion.............................................................................................. 49 
 
III: SAFETY OF INTRACORONARY INFUSION OF 20 MILLION C-KIT  
 POSITIVE HUMAN CARDIAC PROGENITOR CELLS IN PIGS 
 
 Introduction…………………………………………………………… 54 
   
Design and Methods……………………………………………...…… 56 
   
Results………………………………………………………………… 71 
   
Discussion…………………………………………………………..… 84 
 
IV:  A NOVEL POPULATION OF HUMAN CARDIAC PROGENITOR CELLS  
 EXPRESSING STAGE-SPECIFIC EMBRYONIC ANTIGEN-3: PHENOTYPE  
 AND THERAPEUTIC UTILITY IN A MURINE MODEL OF ISCHEMIC  
 CARDIOMYOPATHY 
 Introduction…………………………………………………………… 89 
   
Design and Methods……………………………………………...…… 91 
   
Results………………………………………………………………… 109 















FIGURE          PAGE 
 
 
1.  Stop-flow study experimental protocol and timeline 35 
2.  C-kit positivity, cell product radioactivity, radiolabeling  
efficiency, cell product viability, cell number, and diffusive  
loss of indium-111 oxine. 42 
 
3.  LV ejection fraction 44 
 
4.  Nuclear imaging of hCSC retention. 46 
 
5.  Myocardial hCSC retention at 24 h. 48 
 
6.  Safety Study protocol and timeline. 58 
 
7.  Isolation and expansion of c-kitpos hCPCs 60 
 
8.  Flow cytometric validation and immunocytochemistry of  
 c-kitpos hCPCs. 63 
 
9.  Cumulative c-kit positivity by flow cytometry and Trypan  
 blue cell product viability.   64 
 
10.  Intracoronary infusion of 20 million human c-kitpos CPCs  
 does not impair left ventricular (LV) function or morphology. 72 
 
11.  Intracoronary infusion of 20 million human c-kitpos CPCs does  
 not cause myocardial damage as assessed by cardiac troponin I





12.  Intracoronary infusion of 20 million human c-kitpos CPCs does 
  not cause myocardial damage as assessed by cardiac CK-MB release. 76 
 
13.  Intracoronary infusion of 20 million human c c-kitpos CPCs does  
 not impair renal function. 78 
 
14.  Intracoronary infusion of 20 million human c-kitpos CPCs does not impair  
 liver function………………………………………………………………….. 81 
 
15.  Detection of human CPCs in control versus hCPC-treated pig hearts…………… 83 
 
16.  Cells expressing the embryonic stem cell-associate antigen  
 SSEA-3 are present in the human heart and lack hematopoietic  
 lineage markers (linneg)……………………………………………………….. 110 
 
17.  SSEA-3pos cardiac cells are located within the subepicardium and  
 myocardial interstitium predominantly as solitary cells, and 
 a subpopulation of SSEA-3 positive cells express c-kit, likely  
 representing an intermediate phenotype of cardiac progenitors………………. 112 
 
18.  SSEA-3 immunoselection: Enrichment of pluripotency associated  
 markers, cardiac mesodermal markers, isolation and expansion……………... 116 
 
19.  Characterization of in vitro expanded SSEA-3pos linneg...………………………… 120 
 
20.  Immunophenotype of in vitro expanded SSEA-3pos linneg CPCs…………………. 123 
 
21.  Validation of PCR products……………………………………………………… 125 
 
22.  SSEA-3pos linneg cells display clonogenic and multipotent  
 differentiation capacities expressing mature cardiac markers of  
 myocytes, smooth muscle, and endothelial cells under directed in  
 vitro differentiation conditions………………………………………………... 128 
 
23.  Left ventricular morphometric analyses………………………………………….. 131 
 
24.  Left ventricular volumetric comparison...………………………………………... 132 
 
25.  Ejection Fraction…………………………………………………………………. 133 
 








TABLE          PAGE 
 
1.  Antibodies for flow cytometric analyses…………………………………………... 95 
 
2.  Antibodies for immunocytochemistry and immunohistochemistry……………….. 98 
 
3.  PCR genomic target sequences……………………………………………………. 101 
 
4.  Antibodies utilized in analyses of terminal in vitro differentiation………………... 104 
   









Cardiovascular disease accounts for more than 30 % of global mortality making it 
the largest contributor to death worldwide. In the U.S., coronary heart disease accounts 
for approximately 17 million cases annually1, 2, and there are approximately 5-6 million 
patients who currently have a diagnosis of heart failure. The most prevalent cause of 
heart failure is the loss of viable, functioning myocytes which are replaced by 
noncontractile scar after myocardial infarction, although heart failure from nonischemic 
causes is quickly becoming more prevalent.3  Nevertheless, the majority of treatment 
options (medical therapy, catheter-based or surgical revascularization for earlier stages, 
and mechanical support for later stages) employ strategies to limit further scar formation 
and curtail deleterious adverse cardiac remodeling while enhancing or supplementing the 
function of residual myocardium.4, 5 While some therapies have improved mortality and 
work to provide what is essentially a palliative relief of heart failure symptoms, the issue 
of replacing, reducing, or transforming non-viable scar tissue to functional, contractile 
and supporting cells remains the ultimate goal.  To this end, recent efforts within 
regenerative medicine have been aimed at adoptive transfer of various stem cell  
populations in an attempt to accomplish this “holy grail”.  
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Stem cells are undifferentiated, clonal, self-renewing cells that possess a multi-lineage 
differentiation potential toward terminal mature phenotypes.6 Multiple classifications of 
stem cells exist that describe the degree of lineages to which one cell may commit.  Cells 
that can differentiate to all of the body’s cell types are termed pluripotent or totipotent 
(such as embryonic stem cells), and others with differentiation limited to one or more 
lineages of a particular organ are termed unipotent or multipotent progenitors 
respectively.6  Within this framework various types of stem cells, both pluripotent and 
multipotent, have been evaluated for their utilities in the treatment of heart failure with 
the goal to curatively replace damaged cardiac tissue and not simply to delay progression 
of disease.7, 8   
The recent explosion of regenerative medicine has led to the exploration of a wide 
variety of cell types and their respective cardiac differentiation potentials, both in vitro 
and in vivo.  Knowledge of developmental biology and identification of cellular markers 
associated with known stem/progenitor phenotypes have enabled identification of 
candidate cell types that may have cardiomyogenic potential and repair damaged hearts.  
These include pluripotent embryonic stem cells and induced pluripotent stem cells (and 
their derivatives) as well as postnatal stem cells that persist into adulthood.  Among 
postnatal cells, populations both intrinsic to the heart (c-kit+ cardiac progenitor cells and 
cardiosphere derived cells), and extrinsic to the heart (bone marrow and adipose derived 
cells) are under investigation. Importantly, how, when, and the dosage of these progenitor 
cells that are administered to damaged hearts have been found to drastically impact safety 
and efficacy of cell based therapy affecting engraftment, longevity, and therapeutic 
response, which further adds tremendous complexity independent of the intricate cellular 
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biologic processes.  Intuitively, cells of cardiac origin have demonstrated superior ability 
to adopt more mature cardiac phenotypes9, likely secondary to genetic predisposition 
related to chromatin structure and arrangement, than that of progenitors not of cardiac 
origin.  Moreover, cardiac progenitor cells have demonstrated more robust myocardial 
reparative effects via a variety of mechanisms independent of their direct differentiation 
capacity.9  Of these, c-kit+ cardiac progenitor cells have been the most widely 
investigated.10 These cardiac progenitor cells have largely been the focus of our 
investigations here within the Institute of Molecular Cardiology at the University of 
Louisville.  A brief overarching review of past and present cell based modalities that have 
been evaluated for cardiac repair and regeneration is provided below with expanded focus 
on c-kit+ cardiac progenitor cells as they are specifically relevant to the present work.  
The limitations and gaps in knowledge associated with individual modalities and 
methodologies are highlighted to lay out the rational for the newly conducted studies 
described within the present dissertation.   
 
Cell based therapies for heart failure: Extracardiac cell populations 
Skeletal Myoblasts 
Skeletal myoblasts are cells derived from satellite cells, a skeletal muscle 
progenitor cell population located beneath the basal membrane of myofibers.  Satellite 
cells undergo proliferation in response to injury and promote repair and regeneration of 
skeletal muscle via differentiation into new myotubes and muscle fibers.11, 12 They are 
easily obtained from muscle biopsies, rapidly expandable in vitro, and have shown 
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resistance to hypoxic and ischemic conditions.13, 14 Accordingly, skeletal myoblasts were 
the first cells to be tested in preclinical15 and clinical16 studies of HF.  
The ability of skeletal myoblasts to promote cardiac repair and recovery has been 
evaluated in both preclinical and clinical models of HF. 17-19 Studies using both 
intramyocardial and intracoronary administration of myoblasts demonstrated formation of 
myotubes and viable skeletal muscle-like grafts within damaged cardiac tissue.  Myoblast 
administration was associated with attenuation of adverse ventricular remodeling, 
decreased interstitial fibrosis, and improvement of cardiac performance after ischemic 
injury. Beneficial effects of myoblasts, other than direct supplementation contractility, 
are mediated by the correction of the imbalance between matrix metalloproteinases 
(MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) involved in 
extracellular matrix (ECM) remodeling as well as activation of intrinsic cardiac stem 
cells via the secretion of growth factors.20  
The first human transplantation of myoblasts was performed by Menasche et al. in 
patients with HF secondary to ischemic injury.16, 21 Injection of myoblasts into a scarred 
left ventricular (LV) region at the time of coronary artery bypass grafting (CABG) was 
associated with a significant improvement in LV function and NYHA classification. 
However, some treated patients experienced dangerous arrhythmias, specifically, 
ventricular tachycardia, necessitating implantation of internal cardioverter-defibrillators 
(ICDs). The electrical instability of treated hearts is due to the lack of electromechanical 
coupling, and failure of differentiated myotubes to express key gap junction proteins 
involved in cardiac excitation-contraction coupling, namely connexin.22 This 
phenomenon is likely due to the fact that myoblasts transplanted in injured hearts form 
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skeletal (striated) muscle fibers rather than cardiac muscle.16, 22 Myoblasts have proven to 
be unipotent lacking multipotent plasticity to adopt alternate muscle phenotypes.  
Menasche et al. conducted MAGIC, a phase II randomized, placebo-controlled, double-
blind trial that examined the effects of intramyocardial injection of skeletal myoblasts (at 
two doses: 400 or 800 millions) plus CABG vs. CABG alone (controls) in 97 patients 
with severe LV dysfunction (LV ejection fraction [EF] between 15-35%). No significant 
difference in cardiac function or occurrence of malignant arrhythmias between patients 
receiving myoblasts and controls at the end of 6 months was observed.21 Other 
investigators have used catheter-based intramyocardial injection of skeletal myoblasts in 
ischemic HF.  However, no tangible benefits to LV function or patient quality of life 
were able to be reproducibly obtained that mirrored those in preclinical models.  
Presently, attempts at improving cardiac function and ameliorating HF through the use of 
myoblasts have been all but completely abandoned.20  
Bone marrow cells 
Unfractionated bone marrow mononuclear cells (BMMNCs) are a heterogeneous 
population composed of mesenchymal stem cells (MSCs), hematopoietic stem cells 
(HSCs) such as CD34+ cells, and endothelial progenitor cells expressing CD133 (EPCs), 
as well as more committed cell lineages. BMMNCs, and thereby all the cellular subtypes, 
can be easily obtained in large numbers by standard technique using density gradient 
centrifugation and do not require extensive culture or in vitro expansion.23  They have the 
advantage of being able to be utilized shortly after isolation thus maximizing therapeutic 
utility and maximal preservation of intrinsic differentiation potential that may be 
diminished by prolonged culture in vitro.23-25  Nevertheless, conflicting results have been 
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obtained with preclinical models of acute MI and chronic HF.25 In sheep and pig models 
of ischemic heart failure, BMMNCs (injected directly into the scar tissue) produced no 
improvement in LV function (although one study reported increased angiogenesis and 
reduction in infarct size).23 In contrast, studies in dogs and rats have reported 
improvement in myocardial function and increased angiogenesis.23  
Clinical trials utilizing BMMNCs to treat ischemic heart failure have yielded less 
than exciting results of efficacy although overwhelming safety has been observed without 
any teratogenicity.23 Perin et al. were the first to evaluate the safety and efficacy of 
autologous BMMNCs, injected transendocardially in patients with ischemic HF 
demonstrating statistically significant improvement in LVEF and a reduction in end-
systolic volume in cell-treated patients.26-28 Observations by other investigators using 
BMMNCs seemed to support these findings.29, 30 However, other trials have failed to 
show any tangible benefit of BMMNCs in the setting of acute or chronic ischemic cardiac 
injury.31, 32 The reasons for discrepant results are not apparent. Additional studies using 
intracoronary infusion of BMMNCs in patients with HF have also been conducted.  
Similarly, mixed results have been obtained related to efficacy.  Without exhaustively 
comparing the numerous clinical trials, it may best serve to hypothesize that variations in 
dosages of cells, cellular consistency of specific phenotypes such as CD34+ stem cells or 
MSCs, route of administration such as intramyocardial vs intracoronary, site of injection 
such as peri-infarct border zone or direct cell injection into the scar, and timing of cell 
administration after injury , i.e. chronicity of myocardial dysfunction, may all impact the 
efficacy of BMMNC therapy.   
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As is easily seen, these aforementioned factors apply much more broadly to cell 
based therapies in general and contribute to the totality of lacking knowledge related to 
not only the optimal cell type to administer to sick hearts to induce functional recovery, 
but also the how, when, and where to infuse these cells.  
In efforts to determine if specific cellular subsets within the bone marrow may 
offer superior beneficial effects related to cardiac functional improvement, studies have 
utilized purified mesenchymal stem cells (MSCs)33 as well as CD34+ bone marrow cells. 
MSCs, also known as bone marrow stromal cells, are a subset of non-hematopoietic bone 
marrow cells that are multipotent and plastic-adherent under in vitro expansion culture 
conditions. MSCs have demonstrated chondrogenic, adipogenic, and osteogenic 
differentiation potential.33-35  MSCs have also been reported to differentiate into 
cardiomyocytes36, 37 and endothelial cells38, although this cardiogenic potential remains 
controversial39, 40 as no mature cardiomyocytes with complete functional sarcomeric 
apparatus has been observed to arise from MSCs in vitro. In vivo, mature cardiomyocytes 
observed to possibly arise from implanted MSCs have largely been attributed to fusion 
events in which MSCs and native cardiomyocytes merge to form one cell.40  MSCs 
typically express the cell surface markers CD105, CD73, CD90, CD29, CD44, and 
CD166 but lack hematopoietic markers (CD45, CD34 and CD14/CD11b).34, 35, 41 
The results of MSC administration in animal models of chronic heart failure have 
demonstrated salubrious effects of MSC therapy using various intramyocardial and 
intracoronary injection techniques. Studies utilizing autologous MSCs injected directly 
into myocardial scar, reduced infarct size and attenuated further deleterious LV 
remodeling in a porcine model of ischemic cardiomyopathy (ICM).42  Intramyocardial 
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injection of MSCs in rodent models of both ischemic  and nonischemic cardiomyopathy 
have shown improvement in indices of cardiac function and angiogenesis along with 
reduced myocardial fibrosis.42-46 These and other preclinical studies provided the 
groundwork for randomized, double-blind, placebo-controlled studies using autologous 
and allogeneic MSCs in patients with chronic ischemic LV dysfunction undergoing 
CABG (PROMETHEUS; NCT00587990)47 as well as the POSEIDON trial conducted by 
Hare et al.42 The latter additionally compared three doses of autologous or allogeneic 
MSCs (20, 100, and 200 ×106 cells) in patients with ischemic cardiomyopathy and 
demonstrated that all doses favorably impacted patient functional capacity, quality of life, 
and ventricular remodeling. Further trials using intramyocardial injection of autologous 
and allogeneic MSCs in ischemic and nonischemic CM are currently underway, 
specifically, the CONCERT and SENECA phase I/II clinical trials which were conceived 
and designed here at the University of Louisville within the Department of 
Cardiovascular Medicine in conjunction with the National Heart, Lung, and Blood 
Institute (NHLBI) sponsored Cardiovascular Cell Therapy Research Network (CCTRN). 
I was fortunate to have made substantial contributions to these endeavors under the 
guidance of my mentor, who is the primary investigator of these studies, Dr. Roberto 
Bolli.  
Hematopoietic stem cells reside in the bone marrow and differentiate into cells of 
both myeloid and lymphoid lineages centrally within the bone marrow. EPCs, on the 
other hand, are mobilized into peripheral blood, often in response to ischemic injury, and 
differentiate into endothelial cells peripherally promoting neovascularization (re-
endothelialization).48, 49 CD34 is a typical surface marker of both HSCs and EPCs.50 
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Thusly, CD34+ cells have the capacity to give rise to all blood cell types as well as 
endothelial cells (<1% of nucleated cells in the blood are CD34+). Autologous CD34+ cell 
transplantation has been performed in patients with ischemic51 and nonischemic52, 53 
cardiomyopathy. Injection of CD34+ cells into the peri-infarct regions of the left ventricle 
during coronary bypass surgery produced greater improvement in left ventricular ejection 
fraction than did coronary bypass alone.51 Additionally, a study by Vrtovec et al. 
concluded that intracoronary infusion of CD34+ cells led to a modest increase in 
functional endpoints of ejection fraction and 6-min walk distance and a decrease in levels 
of the cardiac stress marker NT-proBNP.52, 53 Importantly, these beneficial effects were 
sustained over time. Additional studies by the same group have shown reproducibility of 
these results related to cardiac function as well as provided data on the effective 
intracardiac doses responsible for patient response to CD34+ bone marrow cell therapy.   
Adipose-derived MSCs 
Similar to bone marrow, adipose tissue contains a pool of multipotent stem cells, 
designated as adipose-derived MSCs that are able to differentiate into not only mature 
adipocytes but also aforementioned cell types of the mesenchymal lineage.54 Adipose-
derived MSCs have also demonstrated the capacity to upregulate cardiac proteins 
although this differentiation is incomplete as no organized, functional sarcomeric 
structure has thus far been able to be obtained, similar to other studies using bone marrow 
derived MSCs.  Nevertheless, adipose derived MSCs administered in animal models of 
heart failure have shown beneficial effects, mirroring bone marrow MSC preclinical 
studies.54 For example, using a cell sheet technology, Miyahara et al. reported that 
transplantation of monolayer MSCs into infarcted myocardium reversed wall thinning 
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and resulted in improved ejection fraction.55 In another study, the effects of transplanting 
undifferentiated or cardiac pre-differentiated adipose-derived MSCs were compared with 
those of unfractionated BMMNCs in a rat model of chronic ICM.56 One month after 
transplantation into infarcted hearts, undifferentiated adipose-derived MSCs improved 
EF, augmented angiogenesis, and decreased fibrosis to a greater degree than that 
observed with adipose-derived cardiomyogenic cells or BMMNCs injection. 
Additionally, intramyocardial injection of adipose derived MSCs just 1 week after 
coronary occlusion abrogated the declinate in myocardial contractile function and 
enhanced post infarction angiogenesis in rodents.57 Clinical trials utilizing adipose 
derived MSCs are currently underway.58  
Embryonic stem cells (ESCs) and ESC-derived cells 
Embryonic stem cells (ESCs) are pluripotent cells harvested from the inner cell 
mass of pre-implantation-stage blastocysts.59, 60 When cultured in suspension, allowing 
sphere formation during in vitro proliferation leading to formation of embryoid bodies, 
both mouse (m) and human (h) ESCs have demonstrated the capacity to differentiate into 
cells of all three germ layers, namely, ectoderm, endoderm, and mesoderm (including 
cardiac myocytes, endothelium, and smooth muscle cells).59-61 Particularly, hESC-derived 
cardiomyocytes exhibit the morphology of adult cardiomyocytes with expression of 
mature sarcomeric proteins and mature structural arrangement of the contractile 
apparatus.23, 62-64 They also express cardiac-specific transcription factors such as Nkx2.5, 
GATA-4, and MEF2C and display spontaneous beating activity with characteristic atrial, 
ventricular, and nodal action potentials.62-64 The strong cardiogenic potential of ESCs and 
the availability of hESC-derived cardiomyocytes have motivated research into their 
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effects in the treatment of heart failure in preclinical models via replacement of lost 
contractile cells.  
Menard et al. first reported that cardiac-committed mouse ESCs, transplanted into 
infarcted sheep myocardium, engrafted and differentiated into cardiomyocytes and 
improved LV function.65 Similarly, using hESC-derived cardiomyocytes, Caspi et al.66 
and Cai et al.67 reported formation of stable cardiomyocyte grafts, attenuated LV 
remodeling, and improvement in LV systolic function in rat models with old myocardial 
infarction (MI) (although in the latter study they caused formation of teratomas).   More 
recently, studies reporting the use of hESC-derived cardiomyocytes (hESC-CMs) in 
chronic animal models of ischemic cardiomyopathy in other large animals, including 
non-human primates (specifically macaques)68, focused specifically on aspects of 
engraftment, functional integration, and electrophysiological behavior of transplanted 
ESC-derived cardiomyocytes in injured myocardium.  In guinea pig models, Shiba and 
colleagues observed re-muscularization with human myocardium which occupied 
approximately 8% of the scar area. While vehicle and non-cardiac control cell groups 
demonstrated progressive LV dilatation and fractional shortening deterioration, ESC-CM 
recipients demonstrated sustained fractional shortening and displayed overall superior 
fractional shortening relative to controls.69  In addition to improved cardiac function, 
animals transplanted with ESC-CMs also exhibited reduced occurrences of both 
spontaneous and induced ventricular tachycardic events.  Utilizing a genetically encoded 
calcium sensor (GCaMP3), the activity of hESC-CM grafted cells was tracked in vivo 
suggesting successful electromechanical integration of grafted cells with host 
myocardium; however, graft-host coupling in injured hearts was notably heterogeneous.69  
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Similar results were observed in a later study employing hESC-CMs in a chronic non-
human primate model of ischemic cardiomyopathy.68  Here, an unprecedented number of 
hESC-CMs (1 billion) were delivered intramyocardially to macaques 2 weeks following 
ischemia-reperfusion injury.  According to the authors, hearts of hESC-CM recipient 
monkeys demonstrated significant re-muscularization of infarct regions which ranged 
from 0.7 to 5.3% (an average of 3% at 4 weeks and 1% at 12 weeks), comprising 
approximately 40% of the infarct volume.68 Despite the fact that hESC-CMs assumed 
only an immature phenotype, electromechanical junctions were evident among hESC-
CMs and host myocytes shortly after engraftment (2 weeks).  The authors showed 
evidence of electromechanical coupling whereby hESC-CMs exhibited regular calcium 
transients that synchronized with host electrocardiograms.  However, contrary to the 
guinea pig model where hESC-CMs afforded protection against arrhythmias69, increased 
incidence of ventricular arrhythmias was noted in primate that was given hESC-CMs.68  
Strong objections to the validity and applicability of the study by Chong et al.68 
were recently published.  In a commentary, Anderson and colleagues highlight notable 
issues of i.) small number of animals studied; ii.) small size of infarcts;  iii.) a lack of 
infarct size reduction compared to controls in the setting of claims of hESC-CM induced 
remuscularization; iv.) possible off target effects of the zinc finger nuclease methodology 
used for gene targeting of the Ca2+ indicator GCaMP3 that was utilized to assess 
electrical coupling; v.) a lack of assessment of cardiac functional parameters or electrical 
properties; vi.) increased prevalence of cardiac arrhythmias resulting from hESC-CM 
administration; vii.) a lack of long term follow-up to assess true myocyte regeneration 
which is characterized by permanent survival and terminal differentiation of engrafted 
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electrically coupled cells; viii.) a lack of sufficient assessment of teratogenicity of hESC-
CMs given that hESC-derived cells are intrinsically heterogeneous, and one cannot 
guarantee that no cells remain in an undifferentiated, pluripotent state and may therefore 
give rise to malignancies.70  Given the plethora of concerns70, 71, the use of such hESC-
CMs in humans and the conclusions of Chong et al regarding the utility of hESC-CMs in 
treating ischemic cardiomyopathy are untenable. Clear objections to the use of ESCs and 
ESC-derived cells have been made.71  
Despite the well-documented capacity of ESCs for cardiac differentiation, both 
ethical and biological concerns have prevented their use as a treatment modality in 
human patients. Specifically, because of their pluripotency and allogeneic nature, 
adoptive transfer of ESCs is plagued by teratoma formation72, 73 and graft rejection72, 
which essentially preclude the clinical use of these cells. In human clinical research, 
tolerance for even the possibility of tumor formation is zero.  Despite efforts to reduce the 
probability of this occurrence by various ESC manipulations, it is cannot be completely 
eliminated.  Therefore, no clinical trial of ESCs in cardiovascular disease has been 
conducted, as one neoplastic occurrence within a human trial subject would be sufficient 
to all but halt clinical investigation of ESCs for the foreseeable future. However, the 
recent emergence of induced pluripotent stem cells (vide infra), has provided an 
alternative that obviates one of the two major problems inherent in ESC-based therapies – 
graft rejection secondary to allogenicity. 
Induced pluripotent stem cells (iPSCs) 
Takahashi and Yamanaka were the first to produce a population of induced 
pluripotent stem cells (iPSCs) by transducing mouse adult fibroblasts with defined 
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transcription factors (OCT3/4, Sox2, c-Myc, and Klf4) (the “Yamanaka factors”).74, 75 
These iPSCs express ESC surface markers and exhibit morphology and growth properties 
similar to those of ESCs, essentially being reversely reprogrammed from a differentiated 
cell type with finite phenotype toward an undifferentiated ESC-like cell with clonal 
expansion, self-renewal, and multilineage differentiation capacities.74, 75 This discovery 
ultimately resulted in a Nobel prize in 2012.  Research evaluating the differentiation 
capacities of iPSCs demonstrated that the cardiogenic potential of iPSCs is very similar 
to that of ESCs, and that iPSC-derived cardiomyocytes possess functional properties 
typical of cardiac cells, such as spontaneous beating, contractility, and ion channel 
expression.76 Additionally, iPSCs have shown capacity to form endothelial and smooth 
muscle cells. Thus, iPSC-derived cell lines have quickly gained momentum for cardiac 
regenerative applications and multiple strategies have been employed using iPSCs and 
iPSC-derived cells to treat heart failure in preclinical models. 
In 2012, Gu and colleagues demonstrated the intramyocardial delivery of porcine 
iPSC-derived endothelial cells (piPSC-ECs) in murine infarct models yielded significant 
improvements in cardiac function via paracrine-mediated promotion of 
neovascularization and cardiomyocyte survival.77  Congruent with these studies, the 
administration of human iPS-derived mesenchymal stem cells (iMSCs) in a murine 
infarct model was shown to mitigate ventricular remodeling and preserve myocardial 
strain via paracrine-mediated promotion of neovascularization and parenchymal/stromal 
cell integration in infarcted regions.78  Thus, while iPS are heralded for their 
developmental potential, studies such as these suggest their salubrious effects on cardiac 
function are largely mediated through paracrine signaling mechanisms and not direct 
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functional integration with preexisting cardiac cell types.  Such principles have been 
mirrored in swine models of ischemia-reperfusion injury.79, 80  In said studies, human ES-
derived vascular cells (hESC-VCs) were epicardially delivered via a fibrin patch.  Patch-
enhanced delivery of hESC-VCs ameliorated contractile dysfunction and LV wall stress, 
as well improved myocardial perfusion in border zone regions.  Concomitantly, hESC-
VC delivery promoted the recruitment of endogenous c-kit+ cells to infarct zones.  
Further, cardiac improvements were correlated with enhanced myocardial energetics 
assessed via in vivo 31P magnetic resonance spectroscopy-2-dimensional chemical shift 
imaging.79  Shortly thereafter, a similar study was performed by the same group utilizing 
vascular cells derived from human iPSCs (hiPSC-VCs).80  Patch-enhanced delivery of 
hiPSC-VCs in a swine model of ischemia-reperfusion injury ameliorated ventricular 
structural and functional abnormalities, reduced infarct size, enhanced vascular density 
and border zone perfusion, as well as promoted the mobilization of endogenous c-kit+ 
cells to the injury site.  These combined effects had pronounced consequences on border 
zone physiology resulting in enhanced ATP turnover rates and improved contractility.   
The ability of ESC/iPSC-derived vascular cells alone to enhance myocardial 
bioenergetics, border zone contractility, and ventricular function in the face of acute 
injury was startling and left investigators wondering whether the introduction of 
additional cardiac cell types sourced from totipotent precursors would have an even 
greater impact on infarct dynamics and myocardial physiology following injury.  This 
was addressed in the most recent iPSC related study from the Zhang laboratory.81  Here, 
human iPSC-derived cardiomyocytes (CM), endothelial cells (EC), and smooth muscle 
cells (SMC) (totaling 6 million; 2 million per cell type)  ere simultaneously administered 
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intramyocardially in a swine ischemia-reperfusion injury model.  Cells were delivered in 
combination with a 3D fibrin patch infused with insulin growth factor (IGF)-encapsulated 
microspheres.  The results of this study showed improvements in ventricular function, 
infarct size, ventricular wall stress, vasculogenesis, and myocardial metabolism.  Further 
tri-lineage cell transplantation revealed integration of cells into host myocardial tissues, 
arterioles, and capillaries; the quantity of surviving transplanted cells was substantially 
greater when used in conjunction with the IGF-infused fibrin patch.  Just like what was 
suggested in previous studies utilizing ESC/iPSC-derived cell types, the molecular basis 
of the observed improvements in cardiac function and arteriole density, following their 
transplantation in infarct models, was credited to multiple paracrine mechanisms which 
could promote cardiomyocyte survival, neoangiogenesis, and cardiac repair.81                   
Although iPSCs hold great promise for cardiac regeneration, the transcription 
factors used to generate these cells (c-Myc, Oct4, and Klf4) are known oncogenes that 
may induce neoplastic transformation and tumor formation. Newer methods that involve 
only transient expression of the reprogramming factors rather than permanent over 
expression may circumvent this problem.82 Still, other problems with iPSCs include the 
extremely low efficiency of iPSC generation and the variability from one cell line to 
another due to issues such as viral transfection efficiency.83 Technical aspects of these 
phenomena remain outside the scope of the present report.  However, given the rapidity 
in which the technology in this field is evolving, it is possible that these hurdles will soon 
be overcome and iPSC-based approaches will become applicable for therapeutic use in 
the treatment of heart failure; at present, however, iPSCs have not proven ready for 
clinical application. Accordingly, alternative approaches to ESC-(vide supra) and iPSC-
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based therapies continue to be explored using autologous and allogeneic postnatal 
multipotent progenitors. 
 
Cell based therapies for heart failure: Cardiac cell populations 
Brief synopsis of fetal cardiomyogenesis and known cardiac progenitors 
The heart is the first functional organ formed during embryonic development, 
with cardiac progenitors specified in early gastrulation.  Three spatially and temporally 
distinct cardiac precursors have been identified by lineage tracing experiments in 
embryonic development: cardiac mesodermal cells, proepicardial cells, and cardiac 
neural crest cells.  These individual lineages have been established to give rise not only to 
specific cell types but also to regions of the mature heart.84-86  Understanding the 
specification of these lineages in forming the mature heart is crucial if insights into the 
residual progenitors’ capacity to contribute to the contractile, vascular, and interstitial 
compartments, as well as response to injury, are to be gained.  A brief synopsis of 
embryonic cardiac development is provided below.   
 Within the primitive streak, time-dependent differential co-expression of vascular 
endothelial growth factor receptor 2 (VEGR2, KDR, Flk-1) allows the divergence of 
hematopoietic and peripheral vasculature progenitors from the cardiovascular progenitors 
that give rise to the heart and central portions of the great vessels84, 85, 87-89. The latter are 
designated by up-regulation of the T-box transcription factors Eomesodermin (Eomes) 
and mesoderm posterior 1 (Mesp1).  These Mesp1+/Eomes+/KDR+ progenitors give rise 
to cardiac mesodermal cells that create the first and second heart fields (FHF, SHF) with 
thin endocardium and the proepicardium (PE)84, 85, 87-92. Cooperatively, these mesodermal 
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progenitors and their progeny form the near entirety of the adult heart.  The ectodermal 
originating cardiac neural crest cells also contribute to fetal cardiomyogenesis, but their 
contributions to the contractile compartment are thought to be minimal and, therefore, are 
not covered in this review.93-95  
FHF progenitors in the cardiac crescent are exposed to local cytokines and growth 
factors, which induce differentiation and up-regulation of essential cardiac regulators 
such as Nkx2.5, Tbx5, and GATA4, among others. These transcription factors induce 
commitment to myocyte lineage and sarcomeric protein expression.84, 85, 91, 92  Progenitor 
tracking and lineage tracing studies have shown that the progeny of the FHF eventually 
gives rise to the myocytes and some smooth muscle cells that predominantly make up the 
left ventricle and the two atria.  The endocardium may also arise from FHF progenitors as 
early simultaneous development is observed to form the primitive heart tube, although 
efforts are ongoing to further delineate early divergence of these two fields from one or 
more upstream progenitors.84, 85, 87, 93, 94, 96, 97  Subsequent to FHF commitment and 
formation of the primitive heart tube, the SHF progenitors, identified by the expression of 
Isl-1, Nkx2.5, and KDR, begin to proliferate and migrate, undergoing commitment and 
differentiation under the influence of local FGF, BMP, and Wnt signaling.  SHF 
progenitors have been shown to generate myocytes, some smooth muscle, and some 
endothelial constituents of the right ventricle and ventricular outflow tract.84, 85, 90, 98 
Importantly, these Isl-1+ progenitors have been found to lack c-kit and Sca-196, 99, 100, thus 
likely excluding this compartment as a source of residual myogenic progenitors having a 
c-kit+ phenotype.  
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At this stage of cardiac development, the myocardium of the first and second 
heart fields, possessing only a thin endocardial lining within the contorting primitive 
heart tube is essentially naked, lacking adventitia, perforating vasculature, or surrounding 
epicardium.84, 85, 101 These constituents have been traced to arise from  distinct 
proepicardial progenitor populations that express the transcription factors Wilms’ tumor 
protein (Wt1) and Tbx-1884-86, 93, 94, 102, largely giving rise to adventitial and smooth 
muscle lineages, as well as Scleraxis (Scx) and Semaphorin3D (Sema3D), giving rise to 
adventitia and some vascular endothelium not of endocardial origin.103  Some of these 
proepicardial progenitors have been found within endocardial cushions, areas well known 
to be formed by early endocardial progenitors.  This co-localization indicates that these 
two fields undergo intermigration, essentially cooperating to form the mature structures 
of the atrioventricular (AV) valves and cardiac septa through epithelial to mesenchymal 
transition (EMT).61, 104, 105  It is currently unclear whether these proepicardial populations 
stem from Isl-1+/Nkx2.5+ precursors of the SHF or are separately derived lineages.  
Tracing studies show that these progenitors migrate over the surface of the exposed 
myocardium, derived from the first and second heart fields, and form the epicardium and 
epicardium-derived cells (EPDCs). 84, 106-109 Once formation of the epicardium is 
complete, epicardial cells proliferate in a direction parallel to the basement membrane 
(BM), resulting in thickening of the epicardial lining, or perpendicular to the BM, 
undergoing epithelial to mesenchymal transition beginning around E12.5-13.5.  
Ultimately, penetrating mesenchymally-transitioned EPDCs, which populate the 
subepicardial region, migrate inward to form the coronary plexus (which later becomes 
the coronary vasculature, with contributions of endocardium-derived endothelial cells and 
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cardiac adventitial fibroblasts.84-86, 98, 104  Additionally, the epicardium and EPDCs are 
involved in septation and function to stimulate myocardial growth and myocyte division, 
specifically to aid formation of compact myocardium.  Endocardium-derived adventitia 
aids in forming the inner trabecular myocardium.60  
It has recently been suggested that EPDCs may generate cardiomyocytes in fetal 
development, but this is currently unresolved. Questions have been raised regarding the 
specificity of the initial model that used Tbx-18 for in vivo tracing of EPDCs.110, 111 
However, similar subsequent evaluation of EPDCs by Zhou et al using WT1 also 
suggested that EPDCs can in fact contribute to mature cardiomyocytes during fetal 
cardiogenesis although this was rare.109  The same group also performed tracing studies 
of WT1+ epicardial cells in adult mice but did not find that these cells contribute to 
cardiomyocytes or endothelium after infarction; lineage commitment after ischemic 
injury-induced epicardial activation was primarily limited to smooth muscle and 
adventitial cells.109  Importantly, the study did observe that epicardial activation did occur 
as a result of ischemic injury, leading to proliferation and migration of EPDCs into the 
damaged myocardium in a reparative role.  However, the aforementioned findings would 
support the concept that the differentiation capacity of WT1+ epicardial cells that persists 
into adulthood is less than that present in fetal development, because a more limited 
lineage commitment, restricted almost entirely to non-myocytes, was seen in adult 
mice.109 Scx/Sema3D+ cells were found to be a distinct population of proepicardial cells 
having only 33% overlapping co-expression of either WT1 or Tbx-18.  Scx/Sema3D+ 
cells were found to give rise predominantly to coronary endothelial cells and adventitial 
cells with some additional contributions to smooth muscle, and rarely cardiomyocytes in 
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the embryonic heart.103 This disproportionally low magnitude of cardiomyogenic 
potential mirrors that observed by the Zhou et al tracing study of WT1+ cells.109, 112  
Although initial studies in zebrafish suggested that activation of epicardial progenitors 
was responsible for cardiomyocyte replacement after injury, more recent work has shown 
that they act by inducing division of existing cardiomyocytes; epicardial cells were traced 
to give rise only to non-myocyte lineages in that model.86, 103, 113-116  The current 
consensus is that the direct contribution of EPDCs to the myocardium is minimal and that 
cardiomyocyte differentiation is a rarity among EPDCs, at least in the postnatal heart.86  
Recent studies of the origin of the endocardium, its formation, and its eventual 
contribution to mature cardiac lineages have found that its proportional contributions to 
mature lineages is similar to that attributed to proepicardium-derived cells. The 
endocardium arises very early in cardiac embryogenesis, simultaneously with the FHF, 
likely stemming from a common progenitor.  Endocardial cells have been shown to arise 
from Bry+/Flk-1+/Nkx2.5+ progenitors forming the primitive heart tube.101  These 
progenitors are distinct from hemangioblast precursors and are identified by a distinct 
expression profile (an E-cadherinlow, Flk1low, NF-ATc1+ phenotype).117 NF-ATc1 was 
found to be expressed exclusively in endocardium, providing a lineage specific marker 
that enables differentiation of the endocardium from other endothelial cell types.118  
Tracing and knockout studies performed by de la Pompa et al. demonstrated that 
endocardial cells not only contribute to a subset of cardiac endothelial cells, but also are 
integral to cardiac cushion formation, valvulogenesis, septation of the atria, ventricles, 
and aortopulmonary trunks, as well as to guiding myocardial trabeculation.101, 118 These 
processes are governed by EMT of endocardial cells (similar with respect to mechanism 
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and signaling pathways to that widely recognized to occur in EPDCs) that precipitates 
differential commitment to various mature cardiac lineages.104 The complex regulatory 
pathways underlying EMT of endocardial cells (as well as that of EPDCs) involve Notch, 
TGF beta superfamilies, SMADs, Wnt/β-catenin, and bone morphogenic proteins 
(BMPs) signaling among others. Comprehensive reviews of these signaling cascades 
have recently been published.104  NF-ATc1 null mice, which lacked endocardium and 
therefore endocardial contributions to cardiac morphogenesis, showed marked 
abnormalities in trunkal, valvular and septal formation which were ultimately 
embryonically lethal.  Interestingly, myocardial, adventitial, and most vascular 
endothelial compartments were found to be unaffected indicating that the endocardium 
does not contribute significantly to these compartments.101  Similarly, studies in Tie-
1/TEK(Tie2) null mice showed early embryonic lethality with impairment not only of 
endocardium formation but also of valvular and septal derivatives, and a lack of 
myocardial trabeculation.119 Interestingly, there was no impairment of early 
cardiomyocyte formation.119  It remains unclear, however, whether there are 
subpopulations of endocardial cells not defined by NF-ATc1 or Tie1/TEK expression that 
may contribute to these lineages.    
Cardiosphere-derived cells 
Cardiospheres were first described by Messina et al. in 2004.120 Using atrial or 
ventricular human biopsy samples and murine hearts, these authors identified a 
population of cells that grew as self-adherent clusters and showed ability to differentiate 
into cardiomyocytes, endothelial cells, and smooth muscle cells. Messina et al. termed 
these clusters “cardiospheres”. Cardiospheres were also able to be obtained from 
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percutaneous endomyocardial biopsy specimens. Cardiospheres were plated and 
expanded in vitro to yield cardiosphere-derived cells (CDCs)121. Cardiospheres and 
CDCs are a heterogeneous mixture of many different cell types, including cells that 
express endothelial (KDR [human]/ flk-1 [mouse], CD31), stem cell (CD34, c-kit, Sca-1), 
and mesenchymal (CD105, CD90) antigenic markers.120 Importantly, the precursor cell(s) 
that gives rise to cells capable of cardiosphere generation and CDCs has yet to be 
identified.  CDCs were reported to differentiate into electrically stable cardiomyocytes in 
vitro and, to promote cardiac regeneration and improved cardiac function when injected 
into a murine infarct model.121 Johnston et al. reported that intracoronary delivery of 
human CDCs in pigs with old MI resulted in cardiac regeneration, reduction in “relative” 
infarct size, abrogation of adverse LV remodeling, and improvement in ejection 
fraction.122  
One clinical trial has been conducted to date using CDCs in patients with ICM.  
The safety and efficacy of direct intramyocardial injection of CDCs and cardiospheres 
were compared in a porcine model of ICM.  Although CDCs and cardiospheres had 
equivalent effects on ejection fraction, the latter proved superior in improving 
hemodynamics, regional cardiac function, and reducing ventricular remodeling. This 
preclinical work was translated by Makkar et al. in a phase I, randomized trial 
(CADUCEUS) in patients with a recent myocardial infarction and LVEF≤45% but 
≥25%.123 Patients received an intracoronary infusion of escalating doses of autologous 
CDCs (12.5, 17.3, or 25 x 106 cells) or vehicle control with standard medical therapy.  
CDC-treated patients exhibited a 42% reduction in scar size (from 24% to 12% of the left 
ventricle), associated with an increase in viable tissue and regional systolic wall 
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thickening in the infarcted region. CDC therapy failed to increase ejection fraction, 
reduce LV volumes, or improve heart failure functional class or quality of life as assessed 
by standard questionnaire.123 Further studies utilizing CDCs/cardiospheres are currently 
underway.  
C-kit positive cardiac progenitor cells 
The observation of sex mismatched cardiomyocytes of recipient origin in donor 
hearts led to the conclusion that cells circulating in the peripheral blood, likely 
originating from the bone marrow, engraft and transdifferentiate into integrated, 
functional cardiomyocytes.124  Several studies of unfractionated bone marrow and bone 
marrow-derived mesenchymal stem cells (MSCs) have shown beneficial effects, but 
differentiation of these cells into cardiomyocytes seems unlikely125, 126; more likely 
mechanisms include paracrine actions and/or cell fusion of cardiomyocytes and bone 
marrow derived cells.125-127  Importantly, evidence of cardiomyocyte division, coupled 
with carbon-14 labeling studies, has led to the recognition that there is cardiomyocyte 
turnover in the adult heart, fueling the search for a cardiac stem cell compartment that is 
innately endowed with cardiomyogenic potential.128, 129    
In 2003, Beltrami et al. reported the discovery of resident c-kit+ cardiac cells 
(CSCs) that were able to give rise to all cardiac lineages including cardiomyocytes.130 
The initial discovery was based on the presence of the c-kit receptor on hematopoietic 
progenitors; it was postulated that the presence of c-kit may identify a cardiac population 
of myocardial progenitors similar to that of the hematopoietic compartment.130  In fact, 
this is what Beltrami and colleagues found.  They observed co-localization of c-kit with 
Nxk2.5, GATA-4 (transcription factors active in cardiomyogenesis), and Ki-67 (a nuclear 
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antigen associated with cell division) but not with mature sarcomeric proteins, suggesting 
a precursor cell, i.e., a proliferating cell that is apparently committed to cardiac lineage 
but lacks a mature phenotype.  The absence of the hematopoietic markers CD34 and 
CD45 indicated that the cells were not immediately from the bone marrow, and were 
therefore intrinsic to the heart. Therefore, it was concluded that the c-kit+ cardiac cells 
were derived from the embryonic cardiac compartments that give rise to the adult 
myocardium.130      
Since the c-kit receptor plays an important role in prosurvival and pro-
proliferative signaling, the c-kit+ phenotype may represent an intermediate progenitor, 
derived from an upstream c-kit-, more undifferentiated cardiac progenitor in which c-kit 
expression increases in conjunction with cell cycle entry and differentiation.  This 
remains a conjecture, however, as direct observation of this is currently lacking, although 
it is extremely probable.  Beltrami and colleagues also alluded to this possible hierarchy 
in their report of c-kit+ cardiac cells, which were found to largely coexpress Nkx2.5.130 
This postulated upstream resident progenitor in the heart has yet to be identified. 
Evidence of a similar phenotypic progression, now widely accepted, was observed in the 
bone marrow with the isolation in 2003 of c-kit- hematopoietic stem cells, which were 
found to give rise to c-kit+ intermediate phenotypes that ultimately were able to 
reconstitute all mature hematopoietic lineages.131 
Over the last decade, conflicting results have been obtained with respect to the 
cardiomyogenic ability of c-kit+ cardiac cells. In vitro, differentiation of cells from adult 
hearts into mature beating cardiomyocytes has not been reported although expression of 
some sarcomeric proteins has been found 130, 132, 133. In vivo, reports of adult 
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cardiomyocyte formation 130, 132, 134-138 have not been reproduced by several other labs 9, 
10, 139-146. Whether this discrepancy is caused by differences in source (fetal and/or 
neonatal cells vs. adult cells), or culture, isolation, or expansion conditions remains to be 
determined.   
Nevertheless, the ability of human and rodent c-kit+ cardiac progenitor cells to 
ameliorate left ventricular dysfunction and pathologic remodeling and promote 
regeneration has been repeatedly demonstrated by several laboratories in various 
preclinical animal models of acute myocardial infarction.132, 141-143, 145-147 Intramyocardial 
injection of c-kit+ cardiac progenitor cells within the border zones of an infarct 20 days 
after a permanent coronary occlusion in rats resulted in attenuation of LV dilation and 
preservation of LV function.147 Additionally, Tang et al.145 demonstrated that 
administration of CPCs is effective in regenerating cardiac tissue and alleviating post-
infarction LV remodeling and dysfunction when these cells are infused intracoronarily in 
the setting of chronic ICM produced by a temporary coronary occlusion followed by 
reperfusion. One month after coronary occlusion/reperfusion, rats received an 
intracoronary infusion of vehicle or EGFP-labeled cells. Notably, CPC-treated rats 
exhibited more viable myocardium in the risk region, less fibrosis in the noninfarcted 
region, and improved LV function. Interestingly, the number of EGFP+ cells expressing 
markers of cardiogenic commitment was too small to account for the augmentation of LV 
function (EGFP+ cells accounted for only 2.6±1.1% of the region at risk and 1.1±0.4% in 
the noninfarcted region). In short, CPCs did not survive, engraft, or differentiate into 
mature cardiac phenotypes within the myocardium.145 These observations suggest that the 
important mechanism whereby CPCs generate their beneficial effects was likely a 
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paracrine action of donor cells on the endogenous myocardium with secretion of 
cytokines/growth factors locally.  Also, induction of endogenous CPC proliferated and 
differentiated into adult cardiac cells was indicated by the finding that the pool of 
endogenous CPCs expanded to a greater degree in CPC-treated than in control rats.145 
Similar results were obtained with intracoronary infusion of autologous CPCs into a 
large, clinically-relevant porcine model of ICM in which pigs underwent a 90-min 
coronary occlusion followed by reperfusion.139 Intracoronarily delivered stem cells to the 
infarct-related artery using the stop-flow technique produced an increase in ejection 
fraction and systolic thickening fraction in the infarcted left ventricular wall, as well as a 
decrease in left ventricular end-diastolic pressure (LVEDP) and an increase in left 
ventricular dP/dtmax in pigs with old infarcts.139 The encouraging results of these studies 
of intracoronary CSC infusion in the setting of an old MI laid the groundwork for 
SCIPIO, the first clinical trial of c-kit+ CPCs.139, 148 
Because of encouraging results of both preclinical and clinical studies, c-kit+ 
cardiac progenitor cells have emerged as one of the most attractive cell types for 
therapeutic application. At the preclinical level, numerous studies conducted by many 
independent laboratories in a wide variety of animal models of ischemic cardiomyopathy 
have consistently documented salubrious effect of exogenous c-kit+ cardiac progenitor 
cells on left ventricular function and structure, including evidence of regeneration of dead 
myocardium. At the clinical level, a small phase I study (the SCIPIO trial) has 
documented the safety of autologous c-kit+ cardiac cell administration in patients with 
ischemic heart failure.148 Although SCIPIO was not designed to assess efficacy, its results 
suggest that c-kit+ cells may impart beneficial effects on left ventricular function, quality 
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of life, functional class, and infarct size, providing a rationale for larger trials aimed at 
determining efficacy.  Such trials will undoubtedly utilize larger dose(s) of cells than was 
administered to patients within the SCIPIO trial (just 1 million).148 However, no studies 
have evaluated the safety of escalating doses of cells delivered intracoronarily, which 
could have adverse effects such as embolization and resultant myocardial ischemia.  Such 
an event could be catastrophic to already structurally and functionally compromised 
hearts damaged from prior infarction.  
 
Dissertation Research: Overview 
With the work contained in this dissertation, in addition to providing the above 
broad review of clinically relevant past and present cell based therapeutic approaches, I 
sought to expand current modalities of cell based therapies in the treatment of ischemic 
heart failure through discovery and evaluation of novel cardiac cell types and expansion 
of applications of existing approaches using intracoronarily delivered c-kit+ cardiac 
progenitor cells. I evaluated the safety of larger doses of intracoronarily administered c-
kit+ cardiac progenitor cells as well as their intracardiac retention post intracoronary 
delivery within a clinically relevant porcine model of chronic ischemic cardiomyopathy. 
Such data are immediately relevant and translatable to the design of human clinical trials 
utilizing c-kit+ cardiac progenitor cells (CPCs).  Data demonstrating this fact are included 
in two recently published peer reviewed publications and were also presented at the 2015 
Scientific Sessions of the American Heart Association annual meeting by Dr. Roberto 
Bolli.  These data directly aided in the design of the phase I/II clinical trial CONCERT 
that has recently initiated enrollment.  In addition, I provide data related to the discovery, 
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characterization, and therapeutic potential of a novel population of postnatal cardiac 
progenitors, possibly hierarchically related to c-kit+ cardiac progenitor cells, that 
residually express embryonic stem cell associated antigens and are not yet described 
within the literature.  Accordingly, some of the data represented herein remain 
unpublished and highly confidential.  These data will be prefaced in much more detail 
throughout the manuscript (vide infra).   
Hypothesis and Research Aims   
Hypothesis: 
A. The present research seeks to empirically examine the safety of high dose 
intracoronary administration of cardiac stem cells within a porcine model to provide 
relevant information to the design of future clinical trials of cell-based therapy for 
myocardial repair.  B. Additionally, the research seeks test the validity of and provide 
rational for or against the use of the Stop-flow technique during intracoronary infusion 
based on the dogma that Stop-flow is necessary for improved cardiac retention of cells 
post infusion by abrogation of downstream cellular washout.  C. Finally, the research 
seeks to ascertain whether additional populations of cardiac progenitors that may express 
stage-specific embryonic stem cell associated antigens (SSEAs), previously alluded to 
exist within the rodent myocardium), may be found within the human heart.  Could such 
cells be isolated from the human heart, expanded in vitro, and utilized for myocardial 
repair after ischemic injury thus providing an new target cell type to be utilized in future 
human clinical trials  in patients with ischemic heart failure.  
Aims:    
1.  Measure and compare intramyocardial retention of intracoronarily infused  
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CPCs with vs without utilization of coronary stop-flow conditions via radiolabel  
tracking of cell distribution.    
2.  Determine safety of high dose intracoronary CPC administration via  
assessment of myocardial damage/injury via measurement of temporal cardiac  
biomarker release as well as functional parameters measured by 2D  
echocardiography over 1 month following intracoronary infusion. Additionally,  
determine safety of high dose CPC administration related to clinical indices of  
systemic organ function, namely hepatic and renal function.  
3.  In clinically relevant human right atrial appendage samples obtained from  
open heart surgeries, determine if there are intramyocardial populations  
expressing Stage-specific Embryonic Antigens-3&4 that may indicate existence  
of a yet undescribed cardiac progenitor pool. Additionally, characterize this  
population and ascertain in vitro differentiation capacity to possibly relate it to  
one or more embryonic cardiomyogenic compartments.  Finally, determine  
reparative potential of such cells in a model of ischemic cardiomyopathy.  
 
Hypothesis and Aims Summary: 
I hypothesized that higher doses of c-kit+ CPCs delivered intracoronarily in pigs 
with prior infarctions would be safe and not result in myocardial damage via embolic 
phenomena. Furthermore, I hypothesized that intracardiac retention of intracoronarily 
delivered c-kit+ CPCs would be very low, indicating that the salubrious effects observed 
in prior studies were imparted by only a small fraction of the administered dose.  In aim 
1, I utilized indium-111 radiolabeling and nuclear gamma camera imaging to localized 
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the anatomic site of cell deposition/retention and quantify the intracardiac retention of 
cells 24 h post administration to confirm that only a small fraction of cells are actually 
retained within the heart and are responsible for beneficial effects irrespective of any 
attempt to maximize cell retention by coronary stop-flow. In aim 2, , I demonstrated that 
there was no release of cardiac biomarkers or decline in cardiac function indicative of 
myocardial injury after intracoronary administration of 20 million c-kit+ CPCs thus 
confirming safety of doses higher than that previously using in clinical trials to date.    A 
comprehensive review of the literature related to the possible origins of c-kit+ CPCs led 
me to hypothesize that there were yet unidentified upstream progenitors within the heart 
that may give rise to c-kit positive intermediate phenotypes during differentiation. I 
hypothesized that these primitive cells may retain characteristics typical of other 
undifferentiated primitive cells, specifically embryonic stem cell associated antigens that 
may aid in identification and isolation.  In aim 3, I successfully identified cardiac cells 
expressing stage-specific embryonic antigen (SSEA) – 3, demonstrating a partial 
overlapping phenotype with c-kit expression in vivo, and that SSEA-3+ cells possess 








EFFECT OF THE STOP-FLOW TECHNIQUE ON CARDIAC RETENTION OF C-KIT 
POSITIVE HUMAN CARDIAC PROGENITOR CELLS AFTER INTRACORONARY 




Since their initial discovery and characterization130, c-kit+ (c-kitpos) cardiac 
progenitor cells (CPCs) have emerged as a promising modality in the treatment of 
ischemic cardiomyopathy.  Preclinical studies conducted over the last decade have 
reproducibly demonstrated the capacity of in vitro expanded c-kitpos cardiac cells to 
induce myocardial repair and functional recovery.8 These observations led to the Cardiac 
Stem Cell Infusion in Patients with Ischemic CardiOmyopathy (SCIPIO) phase I clinical 
trial, which demonstrated the safety and feasibility of intracoronary delivery of c-kitpos 
CPCs in humans.148  Recently, the safety of even larger doses (up to 20 million in vitro 
expanded c-kitpos CPCs) has been demonstrated in a porcine model and will be discussed 
later (vide infra). 
In SCIPIO148, as well as in almost every trial of intracoronary cell infusion 
performed to date, the cells were delivered with the stop-flow technique149-151; that is, an 
intracoronary balloon was inflated to stop flow within the coronary artery and prevent 
rapid wash out of the cells, thus, in theory, promoting greater cell retention by enhancing 
vascular adhesion and extravasation into the surrounding myocardium.  This approach is  
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being used in most ongoing and planned clinical trials in which cells are infused 
intracoronarily.  Although theoretically attractive, however, the stop-flow technique has 
not been shown to be superior to non-occlusive cell delivery in terms of cell product 
retention. The stop-flow technique is potentially hazardous152, 153, and therefore 
constitutes an impediment to the widespread use of cell therapy in patients with 
cardiovascular disease, particularly when, as is often the case in chronic ischemic 
cardiomyopathy, the culprit coronary arteries targeted for cell delivery are not stented.  
Manipulation of a non-stented coronary artery with an intraluminal balloon under 
pressure carries a significant risk of vascular damage, coronary artery dissection, and 
even life-threatening arterial perforation and rupture.152  In addition, the interruption of 
coronary flow may elicit myocardial injury, either directly from epicardial coronary 
artery occlusion or by distal microembolization of dislodged atherosclerotic plaque 
material154, 155, and may cause arrhythmias in already dysfunctional hearts.  Again, this 
issue is particularly relevant to patients with ischemic cardiomyopathy, whose targeted 
coronary arteries or bypass grafts are often not protected by stents. 
Given the seriousness of the aforementioned complications, objective evidence of 
improved cell retention is essential to justify subjecting patients to increased procedural 
risks in future clinical trials involving intracoronary administration of cell-based 
products. However, as mentioned above, despite the widespread assumption that the stop-
flow technique promotes improved extravasation and cardiac retention of cells, no studies 
have evaluated the utility of the technique using c-kitpos CPCs or any cardiac-derived cell. 
Accordingly, we addressed this issue in a clinically relevant porcine model of ischemic 
cardiomyopathy in which we measured the cardiac retention of 10 million indium-111 
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oxine radiolabeled c-kitpos CPCs infused with or without the stop-flow technique. 
Additionally, this study allows determination of the effective intracardiac retention of 
CPCs that resulted in the salubrious effects of intracoronarily delivered CPCs observed in 
the SCIPIO trial.148 
Methods 
Ethics Statement 
This study was carried out in strict accordance with the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health and the guidelines of the 
Animal Care and Use Committee of the University of Louisville (KY) School of 
Medicine following the guidelines set forth by the 1996 Guide for the Care and Use of 
Laboratory Animals.. The protocol was approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Louisville (IACUC number: 12114).  










Human c-kitpos CSC isolation and flow cytometry 
 Isolation, immunomagnetic selection, and flow cytometric analysis of c-kitpos 
hCPCs was performed as previously described.139, 156  Briefly, human right atrial 
appendage specimens (RAAs) were obtained with Jewish Hospital Institutional Review 
Board (IRB) approval (IRB number 07.0062) from patients undergoing open-heart, on 
pump, coronary artery bypass surgery at Jewish Hospital in Louisville, Kentucky.  All 
patients were between 40 and 80 years of age, so as to approximate the ages of patients in 
the recently conducted SCIPIO trial.148  RAAs were washed several times with PBS and 
were minced to obtain fragments < 1mm3.  The tissue fragments were underwent 
multiple rounds of enzymatic digestion.  Isolated cells were plated in a 6-well plate for 
passage 0 initial expansion.  Passage 1 cells were sorted for c-kit with anti-CD117 
Miltenyi microbeads and a Miltenyi magnetic sorting apparatus per manufacturer’s 
specifications.  Positively selected cells were expanded exponentially over 3-4 additional 
passages to obtain 2-3 x 107 cells per patient.  Multiple patients’ cells were pooled to 
obtain a uniform cell product that was radiolabeled and infused intracoronarily into pigs.  
Cells were assessed for c-kit positivity by flow cytometric analysis at passage 3 after 
fixation and labeling with c-terminal specific Santa Cruz C19 rabbit polyclonal IgG anti-
human c-kit antibody and secondary antibody, a FITC or APC conjugated Invitrogen 
donkey anti-rabbit IgG versus isotype control using a BD LSR flow cytometer.  BD LSR 
DIVA software was used for final analysis of c-kit positivity.   
Cell product generation and indium-111 oxine radiolabeling 
In vitro expanded c-kitpos CPCs were trypsinized and washed with sterile PBS and 
resuspended in Plasmalyte-A solution with ~750 µCi indum-111 oxine, purchased from 
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Cardinal Health, Nuclear Pharmacy Services in Louisville, Kentucky, for 20 min at 37°C 
with 5% CO2. A Capintec CRC-15R Radioisotope Dose Calibrator was used to conduct 
all radioactivity measurements.  After 20 min, the cells were washed twice in 10 mL of 
cold Plasmalyte-A to remove unbound radioisotope.  The cells were resuspended in 1-2 
mL of Plasmalyte-A for final cell count and viability by hemocytometer and Trypan blue.  
A final radioactivity measurement was made to assess percent radiolabeling efficiency.   
 After the intracoronary infusions were completed, tubes, catheters, plastic ware, 
and other materials that had come into contact with the radiolabeled cells were taken back 
to the dose calibrator for radioactivity measurement.  The residual radioactivity was 
subtracted from that of the labeled cell product to obtain the radioactivity of the cell 
product that was administered intracoronarily.  This number was recorded and utilized for 
all subsequent calculations of cardiac cellular retention.  
Radiolabeling efficiency 
 Radiolabeling efficiency was defined as the ratio between the final radioactivity 
of the cell product prior to infusion and the initial dose of indium-111 to which the cells 
were exposed.  
Adjustments for diffusive loss of Indium-111 oxine over the 24 h follow-up and 
calculation of cardiac radioactivity 
 Diffusion of unbound indium-111 oxine out of labeled cells continues over time, 
and this may lead to potential underestimation of cell retention.  Similar observations 
have been made in prior studies.157   
Experiments were performed in triplicate. Ten million cells were radiolabeled 
with indium-111 oxine as described and placed in 5 mL serum-free Ham’s F12 medium 
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for 24 h with periodic media changes. Media was completely changed every 4 h to 
maintain a high diffusive gradient similar to that which occurred in vivo after cell 
infusion.  Extreme care was taken to avoid loss of cells.  After 24 h, cells were 
centrifuged and the cell pellet assessed for radioactivity.  Diffusive loss was quantified as 
percent of expected radioactivity after accounting for radioactive decay over the 24 h 
incubation period.  A correction factor was generated by dividing 100 by this observed 
percent of theoretical maximum radioactivity, so as to account for all infused cells and 
avoid underestimation of intracardiac retention at 24 h.   
The radioactivity measured in all cardiac segments was adjusted according to the 
correction factor (3.52) to obtain the corrected radioactivity for each cardiac tissue 
specimen.  All radioactivities were then summed to obtain the total radioactivity of each 
heart.  This total corrected cardiac radioactivity was divided by the expected maximum 
radioactivity of the infusate (adjusted for time dependent decay) to obtain the percent 
retention of the intracoronarily delivered indium-111 oxine labeled cell product. 
Animal procedures  
Female Yorkshire pigs (39.8 ± 5.2 kg, age 12-18 weeks) were sedated using a 
cocktail of ketamine (20 mg/kg, i.m.) and xylazine (2 mg/kg, i.m.), intubated, and 
mechanically ventilated with 100% oxygen.  Anesthesia was maintained with 0.8-1.5% 
isoflurane.  A femoral artery cut-down was performed and an 8F arterial sheath was 
placed; a 7F Hockey-stick guide catheter was advanced to the left coronary ostium.  An 
angioplasty balloon catheter was positioned in the left anterior descending (LAD) 
coronary artery at a site distal to the first diagonal branch, after which the pigs were 
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subjected to a 90-min LAD coronary occlusion followed by reperfusion by inflation and 
deflation of the balloon, respectively (Fig. ).   
One to two months (45.3 ± 4.5 days) after MI, the pigs were reanesthetized.  An 
angioplasty balloon catheter was placed in the LAD at the site of the previous occlusion. 
Indium-labeled hCSCs were administered with four infusions, each consisting of 3 ml 
over 30 s, with or without concurrent 3-min balloon inflation.  In the pigs with balloon 
inflation, five cycles of 3-min balloon inflation/3-min deflation were performed. The aim 
of the first cycle, which was performed without infusing cells, was to increase 
microvascular permeability in the distal myocardium; during the following four cycles, 
hCPCs were infused into the coronary artery as described above.  In the pigs without 
balloon inflation, hCPCs were infused four times; each infusion lasted 30 s and the four 
infusions were interspaced with intervals of 5 min and 30 s (Fig. 1). 
Twenty-four hours after hCPC administration, the pigs were euthanized and 
various organs (heart, lung, liver, kidney and spleen) were harvested for analysis. 
Immunosuppressive therapy 
Pigs received 15 mg/kg/day of oral cyclosporine (Novartis) orally starting 3 days 
before cell infusion and continuing until euthanasia.   
Echocardiography 
Echocardiograms were obtained at baseline (before the induction of infarction) 
and again 30 d later (prior to radiolabeled hCPC intracoronary infusion) using an HP 
SONOS 7500 ultrasound system (Philips Medical Systems) equipped with a HP 21350A 
(S8) 3.0-8.0 MHz sector array ultrasound transducer. Briefly, pigs were anesthetized and 
placed in the left lateral decubitus position. Temperature was kept between 37.0°C and 
40 
 
37.5°C with a heating pad. The parasternal short-axis view was used to obtain 2D and M-
mode images.148  Systolic and diastolic anatomic parameters were obtained from M-mode 
tracings at the mid-papillary level. Digital images were analyzed off-line by a single 
blinded observer using the ComPACS Review Station (version 10.5) image analysis 
software (Medimatic, Las Cruces, NM 88004, USA) according to the American Society 
of Echocardiography standards.158   
Nuclear imaging and cardiac radioactivity measurements 
 Perfusion fixed porcine hearts were subjected to nuclear imaging and radioactivity 
measurements.  After whole heart nuclear imaging with Picker Prism 2000 XP nuclear 
gamma camera, hearts were bread-loafed into five slices of equal thickness from the apex 
to the base; each slice above the apex was then subdivided into three regions: right 
ventricle, left ventricular free wall, and septum.  The base was divided into right and left 
sections.  The right and left atria were sectioned and placed into independent containers. 
The proximal portions of the great vessels were removed and placed together into another 
container.  All specimens were measured with a Capintec CRC-15R Radioisotope Dose 
Calibrator and the anatomic regions were combined to create a regional distribution of 
radioactivity.  The radioactivity in all regions was then combined to obtain the total 
radioactivity in each heart. The same dose calibrator was used throughout the study.  
Statistics 
 Student’s t-test , one-way ANOVA, or two-way repeated measures ANOVA, as 
appropriate, was employed for comparisons of echocardiographic parameters, 




Flow cytometric analysis 
 Flow cytometric analysis for c-kit expression was performed for seven cell lines 
at early passage as described (c-kit positivity ranged from 72.6% to 90.8%). The mean c-
kit positivity of the cells utilized for the study as assessed by standard protocol was 






Figure 2. C-kit positivity, cell product radioactivity, radiolabeling efficiency, cell 
product viability, cell number, and diffusive loss of indium-111 oxine. A. C-kit 
positivity of individual cell lines is illustrated by black bars, with mean positivity shown 
in white. C-kit positivity ranged from 72.6% to 90.8% with mean c-kit positivity of 
81.6±7.0%. Cell lines were combined to obtain a homogenous cell product.  B. Mean 
final cell product radioactivity of cells infused with continuous flow [Stop-flow (-)] or  
stop-flow [Stop-flow(+)]. C. Indium labeling efficiency of cells administered with or 
without stop-flow. D. Mean cell viability, assessed by Trypan blue, before (black bars) 
and after (white bars) radiolabeling. E.  Number of radiolabeled hCSCs in each group. 
All values are mean±SEM. 
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Final cell product radioactivity, labeling efficiency, cell viability, and cell number 
 Final radioactivity and radiolabeling efficiency were calculated for all cell 
products prior to intracoronary infusion.  No significant difference between cell products 
was observed with regard to the final mean radioactivity (Fig. 2B) (635±74.28 µCi in the 
continuous-flow group vs. 661±63.28 µCi in the stop-flow group) or mean labeling 
efficiency (Fig. 2C) (81.0±8.4% in the continuous-flow group, 84.5±9.8% in the stop-
flow group).  
Cell viability, measured by hemocytometer and Trypan blue, declined in both 
groups as a result of indium-111 oxine radiolabeling. However, no significant difference 
was observed in the viability of the cell products between the continuous-flow 
(85.0±0.81%) and the stop-flow (83.0±0.78%) groups (Fig. 2D). Similarly, there was no 
significant difference with respect to the final numbers of cells infused intracoronarily 
between the continuous-flow (10.1±0.41 x 106 cells) and the stop-flow (9.83±0.25 x 106 
cells) groups (Fig. 2E).   
Echocardiographic analyses 
 Baseline left ventricular (LV) ejection fraction (EF) was not significantly different 
between the continuous-flow group (74.35±4.09%) and the stop-flow group 
(71.16±4.11%) (Fig. 3).  At 30 days after infarction, there was a significant decline in 
both the continuous-flow group (44.57±6.75%) and the stop-flow group (37.79±6.77%).  
The decline in ejection fraction did not differ significantly between the continuous-flow 






Figure 3. LV ejection fraction.  Echocardiographic analyses were performed at baseline 
and again 30 d after infarction prior to intracoronary radiolabeled hCSC delivery to 
measure ejection fraction. Ejection fraction at 30 d after infarction was not significantly 
different between groups indicating similar degree of myocardial injury and functional 





 Myocardial nuclear imaging was performed to visualize the distribution of 
radioactivity and, indirectly, cell retention.  As expected, cell (radioactivity) retention 
was observed in the distribution of the mid-distal LAD within the apical, anteroseptal, 






Figure 4.  Nuclear imaging of hCSC retention. Cell retention was assessed by 
radioactivity and visualized by whole heart nuclear imaging. Radioactivity was observed 
in the distribution of the LAD, specifically, in the anteroseptal, anterior, and anterolateral 
walls of the left ventricle.  Areas of high radioactivity and cell retention are identified by 
the bright orange coloration while areas with no or low radioactivity are identified by 




Cardiac retention of hCSCs  
 Measurements of total cardiac radioactivity demonstrated that the stop-flow 
technique did not result in significantly higher retention of hCPCs at 24 h compared with 
the continuous-flow technique (5.41±0.80% vs. 4.87±0.62% of initial radioactivity, 
respectively, P=0.61) (Fig. 5).  Regional retention was also not significantly different 
between stop-flow vs. continuous-flow (right ventricle: 1.60±0.30% vs. 1.02±0.15%, 
respectively, P=0.12;  LV septum: 1.88±0.43% vs. 1.81±0.33%, P=0.91; LV anterolateral 
wall: 1.17±0.37% vs. 1.10±0.17%, P=0.87; LV apex: 0.23±0.05% vs 0.31±0.11%, 
P=0.56; right atrium:  0.10±0.03% vs. 0.11±0.02%, P=0.81; left atrium: 0.10±0.02% vs. 






Figure 5.  Myocardial hCSC retention at 24 h. Illustrated is the regional distribution of 
radioactivity in the continuous-flow (black) and stop-flow (white) groups. There was no 
significant difference in regional or total radioactivity (cell retention) between the 




CSC distribution in noncardiac tissues 
 In all pigs, three small samples of lung, liver, kidney, and spleen were assessed 
for radioactivity.  Radioactivity was highest in the lung (17.48±0.11% of initial dose), 
followed by the liver (9.52±0.51 of initial dose), kidney (3.08±0.43%), and lastly spleen 
(0.26±0.06%).  Radioactivity was highly variable in different regions of the same organ.   
Discussion 
This study simultaneously addressed three fundamental questions regarding 
intracoronary infusion of c-kitpos hCPCs: i) what fraction of hCPCs is retained in the heart 
24 h after intracoronary infusion?, ii) what may have been the effective dose of CPCs 
responsible for the indications of function benefits observed in the SCIPIO trial? and iii) 
is the stop-flow technique superior to continuous-flow in promoting cardiac retention of 
hCPCs? That is, is the increased risk of procedural complications associated with balloon 
inflation justified by increased hCPC retention?  Our results indicate that, in pigs with an 
old myocardial infarction, intracoronary infusion of hCPCs without coronary occlusion is 
equivalent to intracoronary delivery utilizing the stop-flow technique in terms of cardiac 
hCPC retention at 24 h.  It may also be reasonably inferred that ischemic preconditioning 
with intermittent balloon inflation/deflation, which has been shown to confer 
cardioprotective effects155, does not affect cardiac retention of CPCs, thus eliminating 
this confounder in studies in which cell therapy has shown benefit when true stop-flow 
was utilized in the treatment group but was withheld in the vehicle control group to 
minimize risk of complication.  With either method, we found that only ~4-5% of the 
infused hCPCs remained in the heart 24 h after intracoronary delivery. To our 
knowledge, this is the first head-to-head comparison of cardiac retention after 
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intracoronary delivery of hCPCs (or any cardiac-derived cell) using continuous flow vs. 
stop flow.  
Previous studies have examined the retention of various stem/progenitor cell types 
using various routes of administration, such as intravenous, intracoronary, and 
transmyocardial injections, in clinical and preclinical models.52, 141, 159-165 However, 
studies that specifically compared cell product retention under continuous-flow and stop-
flow conditions have been limited to bone marrow cells, and most have infused cells after 
acute myocardial infarction.159, 162, 164  Doyle et al159 infused 18F-FDG-labeled BMCs 
intracoronarily in pigs after acute myocardial infarction and observed that a single dose 
of cells given with continuous flow was superior to repeated infusions with stop-flow 
with respect to cardiac retention 1 hour later.  Tussios et al164 infused indium-111 oxine-
labeled BMCs intracoronarily into pigs and found no difference in cardiac retention at 
both 1 h and 24 h after infusion comparing the two techniques.  Perhaps of greater 
relevance, Musialek et al. infused 99Tc-extametazime-labeled bone marrow CD34+ cells 
in patients 6-14 days after acute myocardial infarction under continuous and stop-flow 
conditions; they found equivalent cardiac retention (~ 5%) with both techniques at 36-48 
h after infusion162, which is similar to the results of the present study.  Our study differs 
from the aforementioned preclinical studies in that we evaluated cardiac-derived cells and 
used a model of old myocardial infarction (scar), which is more relevant to the clinical 
use of cardiac-derived cells.   
Analysis of various cardiac regions showed that there were no significant 
differences in the distribution of indium-111 oxine-labeled hCPCs between the two 
infusion techniques (Fig. 5). The overall retention of cells observed at 24 h (~4-5%) was 
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comparable to that observed in previous preclinical and clinical investigations using a 
variety of cell types.26, 52, 141, 160, 162, 163, 165-167 Therefore, intracardiac retention may be 
more related to route of administration rather than cell type whether intrinsically native 
heart or from extra-cardiac organs.  We found a relatively high level of radioactivity in 
the apical portions of the right ventricular wall (Fig. 5).  This observation can be 
accounted for by the fact that, in the pig, an accessory arterial branch originating from the 
distal LAD supplies the apical portions of the right ventricle.168, 169 Radioactivity 
measurements of noncardiac organs indicated that the highest deposition of CPCs after 
intracoronary infusion is in the lungs followed by liver, kidneys, and spleen.    
 The specific protocol for the stop-flow technique (one 3-min occlusion without 
cell infusion followed by four 3-min occlusion/3-min reperfusion cycles) was chosen 
because it is the same protocol that was used in the SCIPIO trial. The infusion of 
radiolabeled cells made it impossible to perform histologic analysis of the myocardium, 
because of the prolonged decay period of indium-111 oxine and attendant safety 
concerns. We were unable to ascertain whether remaining CPCs were adherent to walls 
of the microvasculature or had extravasated into the myocardium.  To verify that the 
magnitude of damage produced by coronary occlusion/reperfusion was comparable 
between the two groups of pigs, we assessed LV function before and 30 d after infarction 
using echocardiography.  Our measurements show that, 30 d after infarction, LV function 
did not differ significantly between the two groups, indicating a similar severity of the 
ischemic damage (Fig. 3).     
The choice of the animal model was dictated by considerations related to clinical 
relevance. Clinically, the question of whether the risk of balloon inflation is justified 
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arises most commonly in patients with chronic ischemic cardiomyopathy who have non-
stented target coronary arteries. This issue is less relevant to patients with acute 
myocardial infarction, since in this setting the culprit vessel is usually stented during 
revascularization and the risk of dissection or injury associated with balloon inflation is 
therefore minimized. Accordingly, we decided to use a porcine model of old infarction 
and scarred myocardium, which mimics the clinical setting of chronic ischemic 
cardiomyopathy. Obviously, the effect of balloon inflation could not be studied in 
rodents. We could have used less complex and expensive porcine models (e.g., pigs 
without myocardial infarction or pigs with acute, rather than chronic, myocardial 
infarction); however, these models would not be relevant to the large cohort of patients 
with old stable myocardial infarcts (scars). 
A variety of methods could have been used to assess cell retention at 24 h. The 
advantage of our methodology, based on quantification of residual radioactivity, is that it 
enabled us to assess the left ventricle as a whole.  Alternative techniques such as PCR-
based methods141, 170 have the advantage of high sensitivity and precision in small 
samples, such as in murine hearts; however, they are not applicable to large tissue 
samples because the large amount of native DNA in such samples would cause a dilution 
in the targeted sequences of human genomic DNA of the residual hCPCs.  This would 
lead to an underestimation of cell numbers.  Additionally, PCR-based methods, as well as 
other methods such as fluorescence in situ hybridization of sex-mismatched donor-
recipient pairs171 and nuclear affinity labeling for cell tracking160, enable quantification of 
cell numbers only in small myocardial samples assumed to be representative of the whole 
heart; these numbers must then be normalized to total myocardial weight to calculate 
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global cardiac retention.  Because cells may be distributed heterogeneously within the 
heart, as observed in the present study (Figs. 4 and 5), these methodologies can 
potentially lead to inaccurate quantification due to sampling bias.  We obviated these 
problems by measuring residual radioactivity in the entire heart. 
 In summary, using a clinically relevant porcine model of ischemic 
cardiomyopathy, we have demonstrated that the stop-flow technique does not result in 
superior hCPC retention 24 h after intracoronary infusion compared with non-occlusive 
hCPC infusion.  Therefore, the increased procedural risks associated with balloon 
inflation do not appear to be warranted.  These results have important practical 
implications for the design of future clinical trials in which hCPCs (or other 





SAFETY OF INTRACORONARY INFUSION OF 20 MILLION C-KIT POSITIVE  
HUMAN CARDIAC PROGENITOR CELLS IN PIGS 
Introduction 
C-kitpos cardiac progenitor cells (CPCs) are one of a number of stem/progenitor 
cells described in the mammalian heart and one of the two types ever used clinically for 
cardiac regeneration.130, 148  We recently reported the results of the first in-human clinical 
trial of autologous c-kitpos CPCs in patients with ischemic cardiomyopathy.148 In this 
phase I trial, designed to evaluate the safety and feasibility of intracoronary 
administration of c-kitpos CPCs, 1 million cells were injected in the infarct-related artery 
using the stop-flow technique. The administration of c-kitpos CPCs was shown to be safe 
and there were encouraging results related to efficacy, with a significant improvement in 
left ventricular (LV) ejection fraction in the hCPC treated group. These encouraging 
findings have sparked growing interest in utilizing c-kitpos CPCs in additional trials with 
escalating doses >1 million cells, particularly in light of  reports of dose-dependent 
responses with stem cells.172 However, the safety of higher doses of c-kitpos CPCs has 
never been evaluated in any clinical or preclinical model. 
Intracoronary administration has been utilized with many cell types.  
Mesenchymal stromal cells (MSCs) have been used in a large number of cardiac 
regeneration trials.  Although these cells are usually administered via transendocardial 
injection, a number of clinical trials have used them intracoronarily.173-177  The cell dose 
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in these studies ranged from 1 million to > 100 million cells.173-175, 177, 178 A number of 
other studies are ongoing with intracoronary administration of MSCs (e.g., RELIEF-
NCT01652209). Nevertheless, there still exist important safety concerns with 
intracoronary injection of MSCs.167, 179, 180 Grieve et al. demonstrated that although 
intracoronary infusion of 25 million MSCs was safe, 75 million cells caused biochemical 
and histological myocardial infarction in an ovine model.180 Similarly, Vulliet et al. 
showed a dose-dependent rise in ST segments during intracoronary injection of MSCs in 
all 7 dogs studied.167 The average size of MSCs and BMMNCs is ~21.0±3.3 μm and 
8.6±1.8 μm, respectively.41, 181 At 7 to 10 μm, the typical capillary luminal diameter is 
smaller than the average sized MSCs, the likely explanation for the findings in the 
aforementioned studies.181, 182  In the CADUCEUS trial, 12.5 to 25 million cardiosphere-
derived cells (CDCs) were injected intracoronarily with no significant safety concern.123 
However, administration of 50 million allogeneic CDCs resulted in large infarctions in 
pigs.181 Measuring 20.6±3.9 μm in diameter, CDCs are larger than the average capillary 
diameter, thereby causing microvascular obstruction in that model. Finally, bone marrow 
mononuclear cells (BMMNCs) have almost always been administered intracoronarily. 
Close to 100 phase I and II clinical trials using large numbers of BMMNCs have 
demonstrated that intracoronary administration is safe.183 For instance, within the three 
phase II trials of BMMNCs led by the Cardiovascular Cell Therapy Research Network 
(CCTRN), 100-150 million cells were administered intracoronarily with no 
complications.184, 185 
C-kitpos CPCs are similar in size to the unselected cell population from which they 
are sorted, ranging from ~12 to 20 µm in diameter in suspension.  Therefore, it is 
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conceivable that they could bring about significant microvascular obstruction if 
administered in high enough doses. Therefore, we set out to investigate the safety of 20 
million intracoronarily delivered c-kitpos human CPCs, a dose ~40 times higher than that 
used in our previous porcine study139, in a porcine model, as a preamble to future clinical 
trials. 
Methods 









Human c-kit pos CPC isolation and expansion 
Right atrial appendage specimens were obtained with IRB approval (IRB number 
07.0062) from patients undergoing open-heart, on pump, coronary artery bypass surgery 
at Jewish Hospital in Louisville, Kentucky.  All patients were between the ages of 50 and 
75 years of age, so as to approximate the ages of patients that were included in the 
recently conducted SCIPIO phase I clinical trial.148  Right atrial appendages were 
transported to the cell processing lab under sterile conditions on wet ice.  The tissue was 
washed several time with ice cold PBS to remove gross blood.  Adipose tissue was then 
resected manually from the external surface of the tissue with subsequent repeated 
washing in cold PBS.  The tissue was then manually minced to obtain fragments < 1mm3 
(Fig. 7).  The tissue fragments were then incubated on a shaking incubator at 37°C in 
Worthington Collagenase type II/Hams F12 solution with multiple rounds enzymatic 
digestion.  Once complete, the solution of released cells was centrifuged with discarding 
of the supernatant.  The cells were washed in full growth media consisting of Ham’s F12 
(Gibco), 10% FBS (Thermo Scientific Hyclone), 10ng/ml Recombinant Human bFGF 
(PeproTech), 0.2mM L-Glutathion (Sigma), human Erythropoietin (Sigma), and 100U/ml 
penicillin/streptomycin (Gibco).  The supernatant was discarded and the cells were 
resuspended in full growth media and plated in a 6-well plate for passage 0 initial 
expansion.  Media was changed at 24 h completely.  Additional media changes were 
performed every 3-4 days or if necessitated by visual examination of the culture.  Cells 
were expanded until 70% confluence at which time they were passaged to T75 Flasks for 
additional subconfluent expansion prior to immunoselection for c-kit expression.  Media 
was added or changed partially every 3-4 days for the remainder of the culture process. 
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Cells were passaged 1 time prior to immunomagnetic sorting for c-kit (CD117) using 
Miltenyi immunomagnetic beads according to manufacturer’s recommendations. 





Fig. 7. Isolation and expansion of c-kitpos hCPCs. Right atrial appendages (RAA) were 
harvested with subsequent mechanical and enzymatic digestion to obtain primary 
outgrowth of total adherent cardiac cells. Primary cells were immunomagnetically sorted 




c-kitpos hCPC immunomagnetic sorting (MACS) 
Passage 1 cells at 70-75% confluence in T75 culture flasks were sorted for c-kit 
with anti-CD117 Miltenyi microbeads and Miltenyi magnetic sorting apparatus (Fig. 7). 
Cell sorting was performed through the direct technique. Cells were trypsined and 
washed twice in ice cold MACS buffer made per manufacturer’s specifications.  All 
solutions were cooled on ice prior to beginning the sorting protocol.  Cells were 
immunomagnetically sorted according to manufacturer’s specifications using Miltenyi 
MS columns and pre-separation filters with magnetic stand. Positively selected cells were 
plated in 6-well plates at subconfluence for subsequent in vitro expansion of c-kitpos cells 
(Fig. 7).  Human c-kitpos CPCs were expanded exponentially over 3-4 additional passages 
to ultimately obtain approximately 3 x 107 cells per patient.  Multiple patients cells were 
pooled to obtain a uniform cell product that was ultimately infused intracoronarily into 
the treatment group of pigs (n = 9). Cells were assessed by flow cytometric analysis per 
standard protocol for c-kit positivity at passage 3-4.  Only populations of cells showing 
greater than 70% c-kit positivity were used for the study. 
Flow cytometric analysis and immunocytochemistry 
Cells were trypsinized from dedicated flasks at passage 3-4 per standard protocol. 
Cells were washed 1x in ice cold buffer with 1% bovine serum albumin (BSA)/phosphate 
buffered saline (PBS) buffer followed by a second wash in cold PBS.  Cells were then 
fixed with 15 minutes at room temperature in freshly prepared or commercially 
purchased 4% PFA buffered to pH 7.  Fixed cells were washed twice in PBS.  Cells were 
stained for c-kit directly after fixation.   Cells were blocked for 10 minutes at RT in 1% 
BSA buffer and then stained for c-kit with c-terminal specific Santa Cruz C19 rabbit 
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polyclonal IgG anti-human c-kit antibody for 1 h at room temperature in the dark.  
Isotype rabbit polyclonal IgG in identical concentration was used in parallel as an isotype 
control.  Cells were then washed twice with 1% BSA buffer.  Secondary antibody, FITC 
or TRITC conjugated Invitrogen Donkey anti-rabbit IgG was then added for 1 h at room 
temperature in the dark for flow cytometry or confocal microscopic imaging after cells 
were spun onto glass slides.  Confocal images were taken using Zeiss 510 inverted 
confocal microscope and image processing performed relative to isotype control labeling 
with integral instrument software only.  Flow cytometric analysis was performed using 
BD Accuri C6 flow cytometer.  All analysis gates were set for false positivity of <1% in 
respective isotype controls (Fig. 8).  Accuri C6 software was used for final analysis of c-
kit positivity. Illustrations of flow plots and immunocytochemistry images (Fig. 8) as 
well as data regarding c-kit positivity of all cell lines utilized for the study are shown 
(Fig. 9). Only cell lines with greater than 70% c-kit positivity measured by flow 




Fig. 8. Flow cytometric validation and immunocytochemistry of c-kitpos hCPCs.  
Representative flow cytometric analyses of isotype control (left) and c-kit-labeled cell 
flow plots (center) are shown.  Suspension immunocytochemistry of c-kitpos hCPCs 
showing positive anti-c-kit labeling is shown in the right panels, with DAPI labeled 





Fig. 9. Cumulative c-kit positivity by flow cytometry and Trypan blue cell product 
viability.  The left panel shows c-kit positivity in seven cell lines utilized for the study, 
which averaged 85.6%±1.9% (mean±SEM).  The right panel shows viability of c-kitpos 
hCPCs measured by cellular exclusion of Trypan blue staining prior to intracoronary 




Cell product generation 
Positively selected cells were expanded in vitro for 3-4 additional passages prior 
to intracoronary infusion.  In vitro expanded c-kitpos CPCs were trypsinized and washed 
with sterile PBS and resuspended in 12mL of Plasmalyte-A solution. Final cell count and 
viability by hemocytometer and Trypan blue were performed.    Cell number was 
adjusted by volume to closely approximate 20 million cells in 12mL Plasmalyte-A 
solution. The cells were placed on wet ice and transported to the cath lab for 
intracoronary infusion. 
Ethics Statement 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Louisville (IACUC number: 12114). 
Animal procedures  
Female Yorkshire pigs (weight 32.4 ± 0.7 kg, age: 13.4 ± 0.3 weeks) were used 
for this study. All animal procedures were approved by the University of Louisville 
IACUC (IACUC number 12114) prior to initiation of the study. Pigs were fasted for at 
least 12 h prior to sedation. On the day of cell delivery, pigs received a prophylactic dose 
of antibiotics (Ceftiofur 3 mg/kg, IM) and a preemptive dose of analgesics 
(buprenorphine 0.025 mg/kg, IM).  Pigs were sedated using a cocktail of ketamine (20 
mg/kg, i.m.) and xylazine (2 mg/kg, i.m.).  An intravenous catheter was placed in a 
marginal ear vein for the administration of fluids and drugs. Animal received diazepam (1 
mg/kg IV) to facilitate intubation.  Following adequate sedation, pigs were intubated and 
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mechanically ventilated.  General anesthesia was maintained with isoflurane (1.5% - 
2.0% 50/50 oxygen/nitrogen).  Pigs received aspirin (2300 mg, IV) and heparin (300 
U/kg, IV) before the catheterization procedure. 
A cut-down on the right neck was performed and the right jugular was used for 
placement of a 7-10 F chronic cath polyurethane catheter (Access Technologies or 
Bard/Hickman). This catheter was implanted, secured, tunneled to the back of the neck 
and kept in place for the duration of the 1 month follow-up for serial blood collections; 
using this catheter, blood samples were obtained for serial measurement of cardiac 
markers at baseline (before catheterization procedure) and at 6, 12, 24 h, and 1 week, and 
1 month after cell delivery (Fig. 6). The catheter dead-space was measured and filled with 
heparin (1000 units/mL) after each withdrawal to maintain patency. Care was taken to fill 
the dead-space only with no spillover into the systemic circulation after each blood 
collection.  
At the end of the 1 month follow up, pigs were anesthetized with 22 mg/kg 
ketamine and 2 mg/kg xylazine IM. Pig was transported to the cath lab for final 
hemodynamic measurement.  Animals received diazepam 1 mg/kg IV to facilitate 
intubation.  Animals were then again intubated and ventilated. General anesthesia was 
maintained with isoflurane (1.5% - 2.0% 50/50 oxygen/nitrogen).  Hemodynamic 
variables were monitored and recorded.  After the final hemodynamic recording was 
taken, the animal was deeply anesthetized with 5% isoflurane.  A bolus of 3-6 ml/kg of 3 
mmol/ml potassium chloride solution was injected intravenously until the heart was 
completely arrested.  Asystole was confirmed by cessation of cardiac electric activity 
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from ECG monitoring. The chest was opened via a left thoracotomy, the aorta was 
transected, and the pig exsanguinated. The heart was then harvested. 
Cell delivery / catheterization procedure  
Through a right femoral artery cut-down, a 7F fast-cath sheath was introduced. A 
6 F Hockey-stick catheter (Cordis) was fluoroscopically guided to the left main coronary 
artery. The left main coronary ostium was engaged by the catheter and an angioplasty-
type balloon catheter (Maverick 2.0 x 9 mm) and guide wire (BMW, Boston Scientific) 
assembly was guided into the LAD; the wire was advanced into the mid LAD and the 
catheter telescoped over the wire and positioned just proximal to the 1st diagonal branch. 
The CPC solution (20 million cells in 12 ml of sterile Plasma-Lyte A solution or vehicle, 
divided by 4 injections, 3 ml each, interspersed with 4’30” between each injection) or 
vehicle (12 ml of sterile Plasma-Lyte A solution) was injected manually at a constant rate 
through the central port of the angioplasty balloon catheter over the 3 min.  After the 
procedure, the Hockey-stick catheter, and the femoral sheath were removed and the groin 
access site was closed in 3 layers using 3-0 PDS suture. A transdermal fentanyl patch (2.5 
µg/kg/h) was placed at the end of the procedure for postoperative analgesics.  The pigs 
were weaned from anesthesia, extubated, and moved to a post-operative area for 
postoperative monitoring. Ceftiofur (3 mg/kg, s.c.) was be repeated on day 1 and 2 post-
procedure.   
Immunosuppressive Therapy 
Pigs received 15 mg/kg/day of Cyclosporine A (CsA) starting 2 days before cell 
injection and continuing until the end of follow-up.  CsA (powder from Novartis) was 
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mixed with a tablespoon of grape flavored Kool-Aid powder and ~60 ml of drinking 
water to make a suspension beverage to feed the animal orally. 
Echocardiography 
Echocardiograms were obtained at baseline (before CSC delivery), 24 h, 1 week, 
and 1 month after CSC delivery (Fig. 6) using a HP SONOS 7500 ultrasound system 
(Philips Medical Systems) equipped with a HP 21350A (S8) 3.0-8.0 MHz sector array 
ultrasound transducer. Before the echocardiographic study, pigs were anesthetized 
(isoflurane) and placed in the left lateral decubitus position. Temperature was monitored 
with a rectal temperature probe and kept between 37.0°C and 37.5°C with a heating pad. 
The parasternal short-axis view was used to obtain 2D and M-mode images19. Systolic 
and diastolic anatomic parameters were obtained from M-mode tracings at the mid-
papillary level. Digital images were analyzed off-line by a single blinded observer using 
ComPACS Review Station (version 10.5) image analysis software (Medimatic, Las 
Cruces, NM 88004, USA ) according to the American Society of Echocardiography 
standards.158   
Cardiac biomarkers assays: Troponin I and CK-MB  
Plasma cTnI levels were measured with a pig cTnI ELISA kit according to the 
manufacturer’s instruction (Life Diagnostics, West Chester, PA) at baseline as well as 6, 
12, and 24 hrs, and one week and one month post infusion (Fig. 6). Fresh blood was 
collected with the heparinized tube and then centrifuged to separate plasma from the 
blood sample. Each assay was performed in duplicate and in a blinded fashion. The 
original cTnI data (i.e., the optical density absorbance values acquired from Beckman 
Coulter DU730 Spectrophotometer) were calibrated and converted with cTnI standard 
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curve. The final cTnI results were expressed as nanogram per milliliter plasma (ng/ml). 
All measurements were performed in duplicate.   
Plasma CK-MB concentration was measured via an  ELISA kit (MyBioSource) at 
baseline as well as 6, 12, and 24 hrs, and one week and one month post infusion (Fig. 6). 
Briefly, the 96-well plate was pre-coated with an antibody specific to pig CK-MB. The 
plasma samples were loaded onto the wells and bound by the pre-coated specific 
antibody. Then a biotinylated detection antibody specific for pig CK-MB and Avidin-
Horseradish Peroxidase (HRP) conjugate were added to the wells. After incubation, free 
components were washed away. The substrate solution was added to each well. Only the 
wells contained CK-MB protein, biotinylated detection antibody and Avidin-HRP 
conjugate presented blue in color. This enzyme-substrate reaction was terminated by the 
addition of a sulphuric acid solution, therefore the color turned to yellow. The optical 
density (OD) was measured spectrophotometrically at a wavelength of 450 nm. The 
original CK-MB data (i.e., OD values) in the pig plasma samples were calculated and 
converted with pig CK-MB standard curve. Duplicate assays were performed for each 
sample and CK-MB concentration was expressed as nanogram per milliliter of plasma 
(ng/ml). All CK-MB assays and calculation were conducted in a blinded fashion relative 
to hCSC treated vs control group.  All measurements were performed in duplicate.  
Assessment of renal and hepatic function 
Functions were assessed by measurement of respective biomarkers.  Peripheral 
blood was drawn and complete metabolic panels (CMPs) were obtained in hCSC-treated 
and control groups at baseline and 6, 12, and 24 h, 1 week, and 1 month after 
intracoronary infusion (Fig. 6).  All CMPs were analyzed by the veterinary lab company 
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Antech Diagnostics (Louisville, Ky) in a blinded fashion.  Resultant biomarker values 
were compared with known porcine reference ranges provided by Antech Diagnostic as 
well as with absolute initial baseline values. Changes in blood urea nitrogen (BUN) and 
creatinine (Cr) were used to assess renal function.  Change in AST, ALT, alkaline 
phosphatase (Alk Phos), and total creatine phosphokinase (CPK) were used to assess 
hepatic function.   
DNA isolation from paraffin embedded sections and PCR  
Genomic DNA was isolated from representative paraffin embedded left 
ventricular tissue sections using QIAamp DNA FFPE Tissue Kit (Qiagen) according to 
the manufacturer’s instructions. Samples were analyzed for the presence of human (HLA-
DMA) and pig (Pig Gapdh) genomic DNA using the following primer sets:  
HLA-DMA fwd, 5’-TACAAACCTCAGCTACCTTCGTGGC-3’  
HLA-DMA rev, 5’-AACCCAGCTGACTCTGGGTGG-3’  
Pig Gapdh fwd, 5’-CCCCCTCAGATTTGGCCGCA-3’ 
Pig Gapdh rev, 5’-CACGGGGGCCACTCACCAT-3’ 
For PCR reaction, 100 ng of each DNA sample was amplified in a 20 µl reaction 
for 40 cycles (denaturation at 95 ºC; annealing at 61 ºC; and extension at 72 ºC) using 
Taq 2X Master Mix (New England Biolabs).  Accordingly, the limiting threshold or 
sensitivity of detection of human CSCs approximated 1 hCSC per 15,000 porcine cells. 
Statistical Analyses 
One or two-way repeated measures ANOVA statistical analysis was employed for 
all comparisons of echocardiographic parameters as well as cardiac, hepatic, and renal 
biomarkers between groups across multiple time points where applicable.  All data are 
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represented as means ± SEM. Datasets are illustrated in the supplemental supporting 
information. 
Results  
Intracoronary infusion of 20 million c-kitpos CPCs does not impair LV function or 
structure 
Echocardiographic measurements were performed at serial time points after 
intracoronary infusion of 20 million human c-kitpos CPCs (n=9) or vehicle (n=5) (Fig. 
10). Baseline parameters were not significantly different between the two groups. No 
significant change in left ventricular (LV) function or dimensions occurred as a result of 
the infusion.  For example, LV ejection fraction (EF) did not differ between hCPC-
treated and vehicle controls at any time point (baseline: 55.8±1.8% vs 60.3±2.9%, 
respectively; 24 h: 56.9±1.6% vs 59.2±1.6%; 1 week: 58.2±1.7% vs 58.0±1.6%; 1 month: 
58.0±2.0 vs 59.0±1.1) (Fig. 10A&E); changes within groups compared with baseline 
were also not significantly different (P>0.05). Mean anterior wall thickening fraction was 
examined in the treatment group and was not observed to be significantly different before 
(58.4±4.9%) vs 24 h after CSC infusion (57.5±6.2%), P>0.05 (Fig. 10D). Similarly, there 
was no significant difference in LV end-diastolic diameter, fractional shortening, end-
diastolic volume, end-systolic volume, end-systolic diameter and anterior and posterior 
wall thickness in both systole and diastole.  These data indicate that the intracoronary 




Fig. 10.  Intracoronary infusion of 20 million human c-kitpos CPCs does not impair 
left ventricular (LV) function or morphology.  The line graphs in the top panel show 
individual values of each pig’s progress over time (baseline, 6, 12, 24 h, 1 week, and 1 
month). Individual plots are in yellow, and group means are illustrated by the red line 
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plots. A. ejection fraction (EF). B. LV end-diastolic diameter (EDD). C. LV end-diastolic 
volume (EDV), D. LV anterior wall fractional thickening. The bottom panel shows group 
mean±SEM at each time point for respective LV functional and morphologic indices.  
Green and red bars indicate hCSC-treated and vehicle groups respectively.  E. ejection 
fraction, F. fractional shortening, G. LV end-systolic area, H. LV end-diastolic area, I. 
LV end-systolic volume, J. LV end-diastolic volume, K. LV anterior wall thickness in 
systole, L. LV anterior wall thickness in diastole, M. LV end-systolic diameter, N. LV 
end-diastolic diameter, O. LV posterior wall thickness in systole, P. LV posterior wall 
thickness in diastole. Data are mean±SEM. There were no significant differences 




Intracoronary infusion of 20 million c-kitpos CPCs does not cause ischemic myocardial 
injury 
Myocardial injury resulting from possible micro-embolization and ischemia was 
assessed by serial measurements of plasma cTnI (Fig. 11) and CK-MB levels (Fig. 12).  
In both c-kitpos CPCs-treated and vehicle controls, cTnI levels rose slightly after 
catheterization and intracoronary infusion, peaking at 6 h post catheterization in both 
groups (hCPC treated, 1.3±0.68 vs. 0.08±0.08 ng/ml at baseline; controls, 1.4±0.58 vs, 
0.07±0.08 ng/ml at baseline). In both groups, cTnI returned to baseline by 12 h and 
remained at baseline levels at 24 h, 1 week, and 1 month after infusion. At no time-point 
during the study was there a significant difference in plasma cTnI levels between the two 
groups. In addition, total cumulative myocardial cTnI release did not differ significantly 
between the hCSC-treated and vehicle-treated groups.  Plasma levels of CK-MB 
exhibited a very slight but clinically irrelevant increase from baseline in both groups, 
(0.068±0.01 vs 0.039±0.01 ng/ml at baseline in the treated group; 0.058±0.013 vs 
0.039±0.01 ng/ml at baseline in the control group) peaking at 12 h in the treatment group 
and 24 h in the control group. Importantly, neither peak mean nor cumulative enzyme 
levels differed significantly between vehicle-treated and hCPC-treated groups, indicating 




Fig. 11.  Intracoronary infusion of 20 million human c-kitpos CPCs does not cause 
myocardial damage as assessed by cardiac troponin I (cTnI) release.  A. Individual 
plots of serum cTnI levels (ng/ml) are shown at serial time points (baseline, 6, 12, 24 h, 1 
week, and 1 month).  Green and red plots indicate hCPC-treated and vehicle control pigs, 
respectively.  B.  Group means at each time point are shown. The green and red plots 
indicate hCPC-treated and vehicle control groups, respectively.  The inset in panel B 
shows cumulative cTnI levels. Data are mean±SEM. There were no significant 
differences in plasma cTnI levels over the 1 month follow up between groups (P > 0.05 at 




Fig. 12.  Intracoronary infusion of 20 million human c-kitpos CPCs does not cause 
myocardial damage as assessed by cardiac CK-MB release.  A. Individual serum CK-
MB levels (ng/ml) over serial time points (baseline, 6, 12, 24 h, 1 week, and 1 month). 
Green and red plots identify hCSC-treated and vehicle control pigs, respectively. B. 
Group means at each time point are shown. The green and red plots identify hCPC-
treated and vehicle control groups, respectively.  The inset in panel B shows cumulative 
CK-MB levels. Data are mean±SEM. There were no significant differences in plasma 




Intracoronary infusion of 20 million c c-kitpos CPCs does not impair renal function 
Serum creatinine and BUN levels rose approximated 25% over baseline in the 
first 12-24 h in both the hCPC-treated and the vehicle groups (Fig. 13).  In the treated 
group, creatinine increased from 1.32 mg/dL to 1.68 mg/dL at 6 h after catheterization; a 
similar pattern was observed in the control group, in which creatinine increased from 
1.54 mg/dL at baseline to 2.04 mg/dL at 6 h after catheterization.  Serum creatinine levels 
returned to baseline values in both groups by 24 h, and no changes were observed at 1 
week and 1 month (Fig. 13A).  Serum BUN levels showed a similar pattern of transient 
increase at 6 h followed by a return to baseline levels (Fig. 13B).  There was no 
significant difference at any time point between hCPC-treated and control pigs with 
respect to either creatinine or BUN serum levels, indicating that the slight increases 




Fig. 13.  Intracoronary infusion of 20 million human c c-kitpos CPCs does not impair 
renal function. Renal function was assessed by serum creatinine and blood urea nitrogen 
(BUN) values over serial time-points (baseline, 6, 12, 24 h, 1 week, and 1 month).  A. 
Bar graph of serum creatinine levels in hCPC-treated and vehicle control group .  B. Bar 
graph of serum BUN levels in hCPC-treated and vehicle control group.  Blue and purple 
bars identify hCPC-treated and vehicle control groups, respectively. Upper limits of 
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normal (ULN) and lower limits of normal (LLN) in each graph are depicted by dashed 
lines respectively. Data are mean±SEM. There were no significant differences in serum 





Intracoronary infusion of 20 million c-kitpos CPCs does not impair hepatic function 
Serum AST, ALT, alkaline phosphatase, and total CPK levels were significantly 
higher after catheterization (P< 0.05 vs. baseline) in both hCPC-treated and control 
groups (Fig. 14). Specifically, AST increased to levels four times (200-400 IU/L) the 
upper limit of normal (45-83 IU/L), peaking 24 h after catheterization (Fig. 14A).  ALT 
also increased but did not surpass the upper limits of normal (52-81 IU/L) in either 
treatment (61.8±23.6 IU/L) or control (67.6±23.0 IU/L) groups (Fig. 14D).  There was no 
significant difference between hCPC-treated and control pigs in either AST or ALT, 
indicating that the rise in these markers was not due to the infused cell product. All 







Fig. 14.  Intracoronary infusion of 20 million human c-kitpos CPCs does not impair 
liver function.  Liver function was assessed by serum AST, ALT, alkaline phosphatase, 
and total CK levels at serial time points (baseline, 6, 12, 24 h, 1 week, and 1 month). A. 
Serum aspartate aminotransferase (AST), B. Serum creatine phosphokinase (CPK), C. 
Serum alkaline phosphatase (Alk. Phos.), D. Serum alanine aminotransferase (ALT). 
Upper limits of normal) and lower limits of normal (LLN) in each graph are depicted by 
dashed lines respectively. Data are mean±SEM. There were no significant differences in 
serum AST, ALT, alkaline phosphatase, or total CK levels over the 1 month follow up 




Intracardiac retention of c-kitpos CPCs in pigs 30 days post intracoronary infusion 
 To assess the number of hCPCs retained in the porcine heart 30 days after 
intracoronary infusion, genomic DNA was isolated from anterior portions of the left 
ventricle and analyzed by PCR for the presence of human genomic DNA (HLA-DMA) 
(Fig. 15). No human DNA could be detected in any control (lanes 1-5) or human CSC-
treated (lanes 6-14) LV samples, indicating the retention of human CPCs was minimal 
and/or below the detection limit of our assay (1 hCPC per 15,000 porcine cells).  Samples 
were also analyzed for the presence of pig genomic DNA (Gapdh) as a control for DNA 





Fig. 15.  Detection of human CPCs in control versus hCPC-treated pig hearts. 
Genomic DNA isolated from representative LV sections from control (lanes 1-5) and 
human CSC-treated pigs (lanes 6-14) were analyzed by PCR for the presence of human 
genomic DNA (HLA-DMA). Samples were also analyzed for the presence of pig 
genomic DNA (Gapdh) as a control for DNA quality. Genomic DNA isolated from 
human heart sections was used as both positive and negative control. None of the 





The present study was conducted to assess the safety of intracoronary infusion of 
20 million c-kitpos CPCs.  We have previously found in a porcine model of ischemic 
cardiomyopathy that intracoronary delivery of 500,000 autologous c-kitpos CPCs, which 
is roughly equivalent to 1 million CSCs in humans, does not result in apparent cardiac 
injury.  The SCIPIO trial showed that intracoronary infusion of 1 million autologous c-
kitpos CPCs in humans is safe and may produce beneficial effects on cardiac function, 
myocardial scar size, and functional capacity. However, the dose employed in SCIPIO 
was relatively low (compared with other trials that have infused, for example, 25 
million123 or even >200 million186 cells). Evidence suggests that higher doses of cells 
may be more efficacious.161 It is currently unknown whether doses of hCPCs greater than 
1 million can be safely administered intracoronarily.  Therefore, we conducted the 
present study with a dose of cells 40 times higher than that used in our previous study139 
as a preamble to future clinical trials. To our knowledge, our infused dose of 20 million 
human c-kitpos CPCs delivered intracoronarily is the highest dose ever attempted in any 
clinical or preclinical model using hCSCs.   
The results of the present study indicate that intracoronary infusion of 20 million 
c-kitpos CPCs is safe.  This higher dose did not result in any evidence of myocardial 
injury, impairment in regional or global cardiac function, deterioration of renal or hepatic 
function, or other adverse effects, either in the immediate post-infusion period or during 
the subsequent month, compared with vehicle (Figs. 10-14). Very small, transient 
increases in plasma troponin I were observed after catheterization in both groups (Fig. 
11) but were not associated with any measurable impairment in LV function (Fig. 10). 
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These low-level, transient increases in plasma troponin are not dissimilar from those seen 
in prior studies139; given their low magnitude and brief duration, they are likely 
insignificant. Importantly, since they were observed in both groups, they cannot be 
attributed to the hCPC product.  We suspect that these early transient increases in plasma 
troponin I in both hCPC- and vehicle-treated animals may have been, at least in part, a 
result of the observed impairment in renal function caused by exposure to cyclosporine 
and a large intravenous contrast load.  Indeed, the time-course of renal dysfunction 
coincided with the transient rise and resolution of plasma troponin over the first 12-24 h 
following catheterization.  Renal dysfunction, decreased creatinine clearance, and uremia 
have been implicated in increased plasma levels of troponin in patients without acute 
myocardial injury.187  In clinical studies in which elevations of plasma troponin were 
related to renal dysfunction, acute myocardial injury was excluded by observing a lack of 
parallel elevations in plasma CK-MB.187  This pattern of low-level troponin increase with 
minimal or no concurrent increase in CK-MB during a period of renal impairment 
mirrors the pattern of cardiac biomarkers observed in the present study. It is possible that 
other factors associated with cardiac catheterization also contributed to the slight rise in 
plasma troponin. In any case, the fact that vehicle-treated pigs exhibited similar 
elevations despite receiving no hCPCs indicates the elevations in treated pigs were not 
caused by hCPCs but, rather, by mechanisms that affected both groups.  
Our findings are consistent with previous studies documenting the safety of 
intracoronary infusion (without stop flow) of similar numbers of other cell types, 
including bone marrow derived MSCs.188, 189 Specifically, Suzuki et al188 demonstrated 
the safety and efficacy of 45 million MSCs infused intracoronarily without stop-flow; the 
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authors observed myocyte regeneration and improved cardiac function without any 
evidence of myocardial necrosis related to the infusion.188 The same group observed a 
similar safety and efficacy profile following intracoronary infusion (without stop flow) of 
30 million cardiosphere-derived cells divided among each of three coronary vessels.189 
Again, no significant TnI elevation was observed. 
As mentioned above, after the catheterization procedure renal function was 
transiently impaired in both treated and control groups (Fig. 13), indicating that the 
decline in creatinine clearance was not due to systemic distribution of hCPCs and renal 
microembolization.  The mild degree and brief duration of renal impairment, along with 
the complete return of creatinine and BUN to baseline levels within 24 h after 
catheterization in both groups, indicates that the etiology was most likely related to the 
contrast administered intravenously during coronary angiography.  Contrast-induced 
nephropathy (CIN) is commonly observed in clinical settings, with temporary decreases 
in creatinine clearance that usually return to normal values within 24-48 h.190  
Concomitant exposure of pigs to cyclosporine likely predisposed to the occurrence of 
CIN and decreased creatinine clearance, since both cyclosporine and intravenous contrast 
exposure produce vasoconstriction of renal afferent arterioles190, 191, which in turn 
decreases the glomerular filtration rate.  
A slight, transient impairment in liver function was also observed (Fig. 14). But 
again, this phenomenon was seen in both hCPC-treated and vehicle-treated pigs, and the 
duration and magnitude were not significantly different between groups, indicating that 
the elevated levels of AST, ALT, and alkaline phosphatase were not caused by 
intracoronarily delivered hCPCs.  ALT, being more specific for liver injury than either 
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AST or alkaline phosphatase192, did not increase above the upper limits of normal (51-82 
IU/L) (Fig. 14D).  In fact, a hepatic source of these elevated biomarkers is highly 
unlikely.  While leak of aminotransferases into the systemic circulation can indicate liver 
injury, the liver is not the only source of these biomarkers and caution should be observed 
in clinical interpretation.192 Increases in these biomarkers are also seen with skeletal 
muscle injury.192, 193 In our porcine model, a cut-down procedure was used to provide 
unrestricted access to the femoral artery for arterial sheath and catheter placement.  The 
resultant soft tissue and skeletal muscle injury provides a non-hepatic source of elevated 
transaminases. This is confirmed by the concurrent increase in muscle specific creatine 
phosphokinase (CPK) (Fig. 14B), which mirrored the magnitude and duration of the rise 
in transaminase levels (Fig. 14A). All of these markers returned to baseline levels 
concurrently.  
Despite the high dose of 20 million cells, myocardial retention of c-kitpos CPCs 30 
days after intracoronary infusion was observed to be minimal and below the threshold of 
detection as measured by PCR targeting human genomic DNA.  In our experience, this 
finding is neither surprising nor unexpected.  Previous studies141, 143, 170 have also found 
minimal retention 30-35 days after c-kitpos CPCs administration in rodent models.  
Additionally, in the current study, human c-kitpos CPCs were infused as a xenograft, and 
only cyclosporine was utilized to prevent acute rejection.  The animal’s immune reaction 
to these human cells is not likely to be completely suppressed by cyclosporine alone over 
a 35-day time period, and thus is likely to have contributed to the attrition of the human 
cells via immune clearance.  In a recent study performed to quantify hCPC engraftment 
and retention in pigs after intracoronary infusion of 10 million Indium111-radiolabeled c-
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kitpos CPCs, we found that just 4-5% of the infused cells remained in the entire heart at 24 
h.194 Additionally, in this study we compared intracoronary infusion both with and 
without utilization of the stop-flow technique, and found no significant difference 
between the two methodologies with respect to hCPC retention at 24 h.  This would 
suggest that the negligible level of hCSC cardiac retention observed in the present study 
was not due to the fact that we did not use the stop flow technique.  However, it should 
be pointed out that in the current study we infused cells into normal, noninfarcted hearts 
(this was done in order to maximize the sensitivity of our model in detecting any 
myocardial damage caused by the high dose of 20 million hCPCs).  This may have 
accelerated the disappearance of hCPCs from the myocardium by negatively impacting 
the homing and/or adhesion of the hCPCs to damaged tissue that occurs in the setting of 
ischemic cardiomyopathy.195, 196 
In conclusion, intracoronary infusion of 20 million human c-kitpos CPCs in pigs 
(equivalent to ~40 million hCPCs in humans) does not cause acute myocardial injury, 
impaired regional or global myocardial function, adverse changes in LV dimensions, or 
liver and renal injury.  These results have immediate translational value and lay the 
groundwork for using doses of CPCs >1 million in future clinical trials. Further studies 
are needed to determine whether doses of c-kitpos CPCs >1 million result in greater 




A NOVEL POPULATIONOF HUMAN CARDIAC PROGENITOR CELLS 
EXPRESSING STAGE-SPECIFIC EMBRYONIC ANTIGEN-3: PHENOTYPE AND 




The discovery that the human heart intrinsically possesses cells with multipotent 
and transdifferentiation capacities has overturned the long held dogma that the postnatal 
heart is a static organ.  Numerous cell types have been isolated from the adult human 
myocardium by various methodologies and studied relative to their ability to minimize or 
reverse ischemic myocardial injury either by stimulation of mechanisms that initiate 
reverse remodeling or by induction of myocardial neovascularization and/or formation of 
new viable myocardium.  The most widely studied include c-kitpos cardiac progenitor 
cells (CPCs) and cardiosphere derived cells (CDCs), which have shown to impart 
salubrious clinical effects in patients with ischemic cardiomyopathy.123, 148  Epicardial 
derived progenitor cells (EPDCs) have also been widely characterized, but evaluation of 
their therapeutic potential has been limited to preclinical models. While the embryonic 
origin of adult EPDCs has been widely studied, originating from proepicardial 
progenitors during fetal cardiomyogenesis and persisting into adulthood,84, 197  the 
embryonic origins of c-kitpos CPCs and cells that give rise to CDCs under in vitro 
conditions remain unclear.10  Evidence suggesting the possibility of an upstream c-kit 
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negative progenitor that may give rise to c-kitpos CPCs within the heart may indirectly be 
proposed based on the discovery by Klarmann et al that c-kit positive hematopoietic stem 
cells arise from a c-kit negative, hematopoietic lineage (lin) negative precursor within the 
bone marrow.131  Beltrami et al allude to this hypothetical hierarchy within the heart and 
existence of such a progenitor population that may give rise to c-kitpos CPCs.130 Similarly, 
the mesenchymal phenotype and reported multipotentiality of cells generated by the 
cardiosphere method would indicate that the human heart harbors a yet unidentified 
multipotent mesenchymal stem cell population that may give rise to mature myocardial 
lineages.198  Gaps in knowledge remain regarding intrinsic cardiac progenitor pools 
responsible for myocardial homeostasis and repair because discrete markers that 
distinguish such upstream, undifferentiated progenitor populations remain to be 
identified.  Based on this, we began to explore markers not previously defined within the 
human heart that have been associated with stemness capacity in other stem cell 
populations, and we sought to determine whether such markers could aid in the 
identification of cardiac cell populations that might be utilized for therapeutic purposes.  
Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), 
as well as some tissue specific mesenchymal stem cells (MSCs) from cord blood199, adult 
bone marrow200-202, adipose tissue201, 202, and dermis202-204 have been found to express the 
glycosphingolipids stage-specific embryonic antigens (SSEA)-3 and SSEA-4, antigens 
first characterized in undifferentiated carcinomas.205, 206 SSEA-3 and SSEA-4 expression 
is observed to be lost with lineage commitment and differentiation as the core structures 
of glycosphingolipid expression in stem cells switches from globo- and lacto- to ganglio- 
series.207  SSEA-3 has shown to be more rapidly down regulated than SSEA-4 indicating 
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that the presence of SSEA-3 is associated with a more primitive state than is SSEA-4 
positivity alone.207  The existence of myocardial cells expressing SSEA-4 has been 
previously described within neonatal and some adult cardiac mesenchymal cells202, 208 
although the presence of SSEA-3 expression remained undefined.  Equivalents of human 
SSEA-3 have been previously observed within adult rat myocardium.209 In the present 
study, we sought to ascertain whether the adult human heart harbored a yet unidentified 
population of cells with a stemness associated phenotype expressing SSEA-3, and 
whether SSEA-3 expressing myocardial cells may be utilized in therapeutic applications 
for myocardial repair after ischemic injury.  For the first time, we report the discovery, 
isolation, characterization, and therapeutic potential of a novel population of cardiac 
progenitor cells expressing SSEA-3.  
Methods 
Acquisition of Human Right Atrial Appendage Specimens 
 Right atrial appendage specimens were obtained with IRB approval from patients 
undergoing open heart, on-pump, coronary artery bypass surgery from 2011 to 2015 at 
Jewish Hospital and Kosair Children’s Hospital (IRB number 07.0062) in Louisville, KY.  
All research was performed in accordance with HHS Regulations (45 CFR Part 46) - 
Protection of Human Subjects and respective exemptions.   
Tissue Processing 
Right atrial appendages (~20-400 mg) were rinsed with ice-cold 1X PBS, 
weighed, and manually minced (fragments < 1 mm3) with sterile surgical scissors. Tissue 
fragments were subsequently washed twice in ice-cold Ham’s F12 base media and 
enzymatically digested with Worthington Collagenase type II/Hams F12 solution 
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(1500U/mL; 10 mL per 100 mg of tissue) for 90 min at 37°C with gentle agitation.  
Resultant cells were harvested via centrifugation (400xg for 5 min), and washed in 
SSEA-3 cell growth media consisting of a combination of mTESR1 media (STEMCELL 
Technologies) containing 20% FBS (Seradigm) and basal growth media [Ham’s F12 
(Gibco) supplemented with 10% FBS (Seradigm), 10 ng/ml Recombinant Human bFGF 
(PeproTech), 0.2 mM L-Glutathione (Sigma), 0.005 U/mL human erythropoietin 
(Sigma), and 100 U/ml penicillin/streptomycin (Gibco)].  Ultimately, the mTESR1 and 
basal media were combined in a 60/40 ratio, respectively, to generate the initial passage 
(P0) SSEA-3 cell growth media. Cells were resuspended in SSEA-3 cell growth media 
and plated in 6-well plates for primary expansion (passage 0).  Media was removed at 24 
h and placed in an empty adjacent well to provide further time for adhesion of cells 
remaining in suspension at 24 h.  These were termed secondary cultures.  2 mL of fresh 
SSEA-3 cell growth media was added to the primary wells.  24 h later, media was 
changed in secondary cultures.  Additional media changes were performed every 3 days 
in both primary and secondary cultures.  Cells were expanded until 70-80% confluence at 
which time they were passaged to T75 Flasks (passage 1) for additional expansion prior 
to immunoselection for SSEA-3 expression.  Primary and secondary unsorted cultures 
were combined at the time of passaging to T75 flasks.  Illustrations of the tissue 
processing and initial cell expansion are similar to what was demonstrated in Figure 7. 
FACS sorting of SSEA-3pos linneg cells 
 Passage 1 cardiac cells were trypsinized and sorted for SSEA-3 expression.  
Briefly, cells at 70-80% confluence were trypsinized, washed with ice-cold MACS 
buffer, and labeled with Ebioscience PE- or Alexa-488-conjugated Rat IgM Anti-
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Human/Mouse SSEA-3 for 30 min per the manufacturer’s instructions. Cells were sorted 
using a Beckman Coulter MoFlo cell sorter.  Gates were set to isolate the highest 1-2% 
SSEA-3 positive events as well as the least positive (SSEA-3 negative) events.   
Immunomagnetic sorting for SSEA-3pos linneg cells 
Passage 1 cells at 70-80% confluence were immunomagnetically sorted for 
SSEA-3 according to the manufacturer’s specifications using Miltenyi MS columns in 
conjunction with pre-separation filters.  Briefly, cells were trypsinized, washed twice in 
ice-cold MACS buffer (1% BSA), suspended in 300 µl 1% BSA MACS buffer, and 
incubated with 15 µl of primary antibody (Ebioscience PE-conjugated rat IgM anti-
human/mouse SSEA-3) for 20 min. Subsequently, cells were washed with 1% BSA 
MACS buffer, suspended in 80 µl 1% BSA MACS buffer, and incubated with 20 µl 
Miltenyi Mouse IgG anti-PE microbead antibody for 20 min.  Cells were then washed in 
10 mL sterile 1% BSA MACS buffer, suspended in 500 ul 1% BSA MACS buffer, and 
loaded onto a primed magnetic column with a 30 µm pre-separation filter. Elution 
procedures were performed according to the manufacturer’s MS column protocol.  
Positively selected cells were plated in T75 flasks at subconfluence for subsequent in 
vitro expansion of human SSEA-3pos linneg cells.  Human SSEA-3pos linneg cells were used 
immediately or expanded exponentially over 2 additional passages to obtain 
approximately 3-20 x 106 cells for use in both in vitro and in vivo studies.  Cells were 
assessed by flow cytometric analysis for SSEA-3 positivity at passage 2 following 
immunomagnetic sorting.   
Flow cytometric analysis  
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Cells were trypsinized from dedicated flasks at passage 2 with TrypLE (Life 
Technologies) and then washed 2 times with 1% BSA MACS buffer (Miltenyi).  Cells 
were incubated with Ebioscience rat IgM anti-human SSEA-3 Alexa Fluor 488-
conjugated antibody for 45 min.  Isotype control Ebioscience Alexa Fluor 488-conjugated 
Rat IgM was used in parallel to establish gating for flow cytometric analyses.  All 
antibodies were used at manufacturer suggested concentrations.  Flow cytometric 
analysis was performed using a BD Accuri C6 flow cytometer or BD LSR flow 
cytometer. Gates were set for false positivity of <1% in respective isotype controls.  
Figures and illustrations of resultant flow plots were obtained by generating jpeg images 
directly from the instrument without the use of any additional software. A comprehensive 




Flow Cytometry     
Marker Manufacturer Species (anti-human) Fluorochrome(s) 
        
SSEA-3 Ebioscience Rat IgM 
unconjugated, alexa-
488, PE 
SSEA-4 Ebioscience Mouse IgG3 
unconjugated, alexa-
488, PE 
KDR R&D systems Mouse IgG1 
unconjugated, alexa-
700 
CD31 BD Mouse IgG1 v450 
CD31 Ebioscience Mouse IgG1 PE 
c-kit Ebioscience Mouse IgG1  PE, APC  
c-kit Sant Cruz Rabbit IgG unconjugated 
CD34 BD Mouse IgG1 v450 
CD34 Ebioscience Mouse IgG1 APC 
CD45 BD Mouse IgG1 v450 
CD45 Ebioscience Mouse IgG1 ACP 
CD105 Ebioscience Mouse IgG1 PE, APC, eFluor-450 
CD73 Ebioscience Mouse IgG1 PE 
CD90 Ebioscience Mouse IgG1 PE, APC 
CD29 Ebioscience Mouse IgG1 APC 
CD44 Ebioscience Rat IgG2b efluor-450 
CD166 Ebioscience Mouse IgG1 PE 
HLA-I BD Mouse IgG1 v450 
HLA-II BD Mouse IgG PE 
TRA-1-60 Ebioscience Mouse IgM PE 
TRA-1-81 Ebioscience Rat IgG2a APC 
CD15 BD Mouse IgM APC, v450 
    
Isotype controls:     
Species Manufacturer Fluorochrome(s)   
Mouse IgG1 Ebioscience 
unconjugated, FITC, alexa-
488, PE, APC, eFluor-450   
Mouse IgG3 Ebioscience 
unconjugated, FITC, alexa-
488, PE   
Rat IgM Ebioscience unconjugated, alexa-488, PE   
Mouse IgG1 R&D unconjugated, alexa-700   
Rabbit IgG 
Novus/Santa 
Cruz unconjugated   
        
Secondary antibodies:     
goat anti-mouge IgG   Life technologies alexa-488,PE , APC 
donkey anti-mouse IgG   Life technologies alexa-488, PE, APC 
goat anti-rabbit IgG   Life technologies alexa-488, PE, APC 
goat anti-rat IgM   Life technologies alexa-488, APC 
        
Antibodies : used per manufacturer's 





Right atrial specimens were cut longitudinally into 2-4 mm sections and fixed for 
24 h with 10% neutral buffered formalin.  Tissue fragments were ethanol dehydrated, 
xylene cleared, and paraffin embedded. Paraffin embedded specimens were sectioned (4 
µm) using a microtome, deparaffinized, and rehydrated.  Antigen retrieval was performed 
by incubating sections with DAKO citrate buffer solution for 10 min at 95°C. Slides were 
next blocked in 5% BSA for 1 h prior to immunostaining. Immunostaining for SSEA-3, 
SSEA-4, and c-kit was performed by staining overnight at 4°C with primary antibodies. 
Primary antibody staining for α-sarcomeric actin, myosin heavy chain, and CD45 was 
performed at room temperature for 1 h.  After primary antibody labeling, the sections 
were washed 3 times in 1X PBS for 3 min. Sections were incubated at room temperature 
for 1 h with secondary antibodies, counterstained with DAPI, and permanently mounted 
using vectashield. Images were taken on a Zeiss 510 confocal microscope and analyzed 
with the accompanying Zeiss software with optimization of contrast and brightness 
applied globally to the entire image.  No extrinsic software was used to process or alter 
images.  
Immunocytochemistry 
SSEA-3pos linneg cells were either seeded on chamber slides or immunolabeled in 
suspension for immunocytochemical characterization.  In both cases, primary antibody 
labeling for SSEA-3, SSEA-4, and other cell surface markers was performed on live cells 
followed by fixation in buffered 4% PFA, methanol permeabilization for additional 
intracellular staining, and secondary staining with fluorophore conjugated antibodies.  
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Briefly, cells that were seeded onto chamber slides were allowed to attach 
overnight.  Slides were then washed with 1X PBS and stained live with anti-human 
SSEA-3- and SSEA-4-unconjugated antibodies (Ebioscience at 1:100 dilutions) for 1 h at 
room temperature in 1% BSA MACS buffer.  Slides were subsequently washed with 1X 
PBS for 10 min, fixed with 4% PFA (Sigma) for 15 min at room temperature, and washed 
with 1X PBS.  Cells were permeabilized with methanol for additional intracellular 
immunostaining in appropriate cases.  Slides were incubated with secondary antibodies 
conjugated with fluorophores (FITC, PE, TRITC, or APC) at room temperature (all 
secondary antibodies were obtained from Life Technologies).   After secondary labeling 
and nuclear counterstaining with DAPI, slides were washed with 1X PBS and images 
acquired.  
Suspension immunostaining was performed with similar antibody concentrations, 
incubation periods, fixation steps, and secondary antibody labeling as previously 
described, but was followed with adhering cells to microscope slides via a Cytospin and 
mounting with Vectashield mounting medium (Vector Labs).  As before, all images were 
taken with a Zeiss 510 confocal microscope and analyzed with the accompanying Zeiss 
software.  Image processing was performed relative to isotype control labeling with 
integral instrument software only.  Modifications to brightness and contrast of images 
were applied to the entire image fields.  No accessory image software was utilized to 
adjust images.  A list of antibodies utilized for immunohistochemistry/cytochemistry is 






Marker Manufacturer Species (anti-human) 
      
hNA Millipore Mouse IgG1 
SSEA-3 Ebioscience Rat IgM 
SSEA-4 Ebioscience Mouse IgG3a 
WT-1 Sigma Rabbit IgG 
NANOG Abcam Rabbit IgG 
OCT4 Ebioscience Rat IgG 
c-kit DAKO Rabbit IgG 
c-kit Santa Cruz Rabbit IgG 
CD45 DAKO Mouse IgG 
Tryptase DAKO Mouse IgG 
Sarcomeric actin Sigma Mouse IgM 
a-Myosin heavy chain Abcam Mouse IgG 
Smooth muscle actin Sigma Mouse IgG 
alpha-tubulin Abcam Mouse IgG1 






Cell population doubling times were calculated by exponential regression, where 
doubling time (d) can be obtained by noting the number of final cells at time t [N(t)], the 
initial number of cells seeded for expansion C, and the time the culture was allowed to 
expand in hours t within the formula N(t)=C2t/d.  Doubling times at passage 2-3 were 
recorded and average doubling times for SSEA-3pos linneg cells at passage 3 calculated.  
Cell counts were performed by hemocytometer and Trypan blue in duplicate. 
Clonogenicity 
Freshly MACS sorted human cardiac SSEA-3pos linneg cells were seeded onto 
Terasaki plates using the limiting dilution technique.  Wells with more than one cell were 
marked and excluded from further analysis.  In total, fifteen 72-well Terasaki plates were 
seeded per patient.  Six patients were utilized for the assay to calculate mean 
clonogenicity of human SSEA-3pos linneg cells. Clonogenicity was defined as a visually 
verified single cell proliferating to form a colony that completely covered the well.  Wells 
that had single cells that did proliferate but spontaneously senesced and did not result in 
complete well coverage were deemed “negative”.  The number of colonies formed was 
divided by the original number of visually verified single cell wells to obtain a percent 
for each patient’s cells. The percentages for each patient were averaged to obtain a mean 
clonogenicity for human cardiac SSEA-3pos linneg cells.   
qPCR 
Total RNA was prepared from MACS/FACS sorted SSEA-3pos linneg and SSEA-
3neg linneg cells using PureLink® RNA Mini Kit (Life Technologies). cDNA was 
synthesized from total RNA using the High-Capacity cDNA Reverse Transcription Kit 
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(Life Technologies) with random hexamers primers according to the manufacturer's 
instructions. Real-time PCR was performed using the Fast SYBR® Green Master Mix 
(Life Technologies) per the manufacturer’s protocol. Reactions were performed in 
duplicate on a 7900 Fast Real-Time PCR System (Applied Biosystems) at 95 °C for 30 s 
and 40 cycles of 5 s at 95 °C, and 30 s at 60 °C. A negative control with RNA instead of 
cDNA was carried out, and the integrity of PCR was verified by dissociation curve 
analysis. Relative gene expression was quantified from fluorescence cycle threshold (Ct) 
values using the ΔΔCt method. Primer sequences for all targets are listed in supplemental 










OCT4 GATGTGGTCCGAGTGTGGTTCT TGTGCATAGTCGCTGCTTGAT 
MIXL1 GGATCCAGGTATGGTTCCAG GGAGCACAGTGGTTGAGGAT 
NANOG  GCAGAAGGCCTCAGCACCTA AGGTTCCCAGTCGGGTTCA 
TBX5 TTCTGCACTCACGTCTTTCC TGGCAAAGGGATTATTCTCA 
TBX18 CAACAGAATGGGTTTGGAAG AAGGTGGAGGAACTTGCATT 
TBX20 AGCTTTGGGACAAATTCCAT CTTGGCCTCAGGATCCAC 
NKX2.5 CCCCTGGATTTTGCATTCAC CGTGCGCAAGAACAAACG 
GATA4  AAGACACCAGCAGCTCCTTC TGTGCCCGTAGTGAGATGAC 




TERT CGTCGAGCTGCTCAGGTCTT AGTGCTGTCTGATTCCAATGCTT 
WT1 CCAGCCCGCTATTCGCAA CGAGTACTGCTGCTCACCCA 
IGF-1R TGTCCTGACATGCTGTTTGA AGGCTCCATCTCCTCTTTGA 
GAPDH  TCAGACACCATGGGGAAG ACATGTAAACCATGTAGTTGAG 
Beta2 
microglobulin  AATGCGGCATCTTCAAACCT TGACTTTGTCACAGCCCAAGATA 
OCT4 GATGTGGTCCGAGTGTGGTTCT TGTGCATAGTCGCTGCTTGAT 
NANOG  GCAGAAGGCCTCAGCACCTA AGGTTCCCAGTCGGGTTCA 
NKX2.5 CCCCTGGATTTTGCATTCAC CGTGCGCAAGAACAAACG 
GATA4  AACGACGGCAACAACGATAAT GTTTTTTCCCCTTTGATTTTTGATC 
MEF2C CTGGCAACAGCAACACCTACA GCTAGTGCAAGCTCCCAACTG 







In vitro differentiation 
 For myogenic differentiation, cells were expanded in T75 flasks one passage after 
sorting to obtain approximately 3-5 million SSEA-3pos linneg sorted cells.  Cells were 
trypsinized, seeded at a density of 104 cells/cm2 in 6-well plates, and allowed to attach 
for 24 h in SSEA-3 cell growth media.  Growth media was changed to myogenic 
differentiation media [DMEM-LG (GIBCO), 5% horse serum (Life Technologies), 10-
5M dexamethasone (Sigma), 0.75% DMSO (Sigma), 20 mmol/L ascorbic acid, 0.1% ITS 
liquid media supplement (Sigma),  0.1% NEAA (Lonza), and 100 U/mL Pen-Strep.  
Media was changed every 48 h without passaging for 35 days.  Cells were harvested by 
trypsinization at various time points for western blot analysis for myocyte and smooth 
muscle contractile proteins.  Additionally, cells were trypsinized and reseeded on 
chamber slides for contractile protein immunostaining and confocal microscopy.  
Endothelial differentiation was induced by changing full growth media to EGM-
2MV (Lonza) media supplemented with 60 ng/mL VEGF (PeproTech).  EGM-2MV 
media was replaced every 48 h during the 10 day duration of endothelial differentiation.  
Cells were trypsinized at 90% confluence and reseeded at 40% confluence when visually 
indicated in T75 flasks.  Cells were trypsinized and submitted for flow cytometric 
analysis for CD31 expression at days 0, 4, and 10 for comparison.  
Western blot analyses 
Cells were trypsinized, washed with 1X PBS, suspended in cell lysis buffer (1% 
NP40, 150mM NaCl, 20mM Tris-HCl, 1% Triton X-100, 4mM PMSF, 1:100 Proteinase 
Inhibitor Cocktail), and briefly sonicated. Whole cell lysates were centrifuged at 14,000 x 
g for 20 min and resultant lysate protein concentrations determined using Bio-Rad 
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Protein Assay Dye Reagent (Cat#500-0006).  Whole cell lysates (15-40 µg of protein) 
were resolved on 10-12% SDS-PAGE gels (Reagents from Bio-Rad), transferred to 
PVDF membranes, and blocked in 3% milk TBST buffer at room temperature for 30 min. 
Membranes were subsequently incubated with primary antibody in blocking buffer (3% 
milk in TBST) overnight at 4°C, washed in 1X TBST, and incubated with HRP-
conjugated secondary antibodies at RT for 1 h. Membranes were then rinsed with 1X 
TBST and proteins detected using enhanced chemiluminescence substrate (HyGOL, 
Denville Scientific, Cat#E2500) according to the company instructions. Western blot 




Marker Manufacturer Cat# Species Mw Usage 
NKX2.5 abcam ab91196 Ms  IgG1 35kDa WB, 1:1000  
NKX2.5 abcam ab106923 Gt  IgG 35kDa WB, 1:1000  
 Brachyury 
(T) 
abcam ab20680 Rb IgG 




sm-MHC Sigma M7786 Ms IgG1 200kDa WB: 1:2000   
 SMA Sigma A5228 Ms, IgG2a  42kDa 
WB: 
1:10000   
α-SA Sigma A7811 Ms IgG 42kDa 
WB:higher 
1:2500  





Ms, IgG2b 250kDa 
WB: 1:500-
1000 
CX43 Sigma C6219 Rb, IgG 43KDa WB: 1:8000 
 WT1 Sigma WH0007490M1 Ms IgG2bk 56KDa WB, 1:500  
KDR Abcam Ab9530 Ms, IgG1 220KDa WB, 1:500  
KDR Sigma SAB4300657 Rb, IgG 220KDa WB, 1:500  





Cell Signaling  
Tech 




Cytokine Array  
5×106 SSEA-3pos linneg or dermal fibroblasts were seeded in culture flasks in 
identical conditions with FBS‐free F-12 media for 24 h. The supernatants (conditioned 
media) were collected and the secretion of various cytokines was visualized by a semi-
quantitative Ab array (R&D biosystems). Intensity was determined using ImageJ 
software (NIH) according to manufacturer’s specifications.   
Animal studies 
This study was performed in immunodeficient NOD/SCID (NOD.CB17-
Prkdcscid/J) female mice (age ~4 months), purchased from The Jackson Laboratory (Bar 
Harbor, ME). All mice were maintained in micro-isolator cages under specific pathogen-
free conditions in a room with a temperature of 24℃, 55–65% relative humidity, and a 
12-h light–dark cycle. 
Murine Model of Acute Myocardial Infarction and Intramyocardial Cell Delivery 
The murine model of myocardial ischemia and reperfusion has been described in 
detail20. Briefly, mice were anesthetized with sodium pentobarbital (60 g/kg i.p.) and 
ventilated using carefully selected parameters. The chest was opened through a left 
anterolateral thoracotomy, and a nontraumatic balloon occluder was implanted around the 
mid-left anterior descending coronary artery using an 8–0 nylon suture. To prevent 
hypotension, blood from a donor mouse was given at serial times during surgery. Rectal 
temperature was carefully monitored and maintained between 36.7 and 37.3 ℃ 
throughout the experiment. In all groups, myocardial infarction (MI) was produced by a 
45 min coronary occlusion followed by reperfusion.  
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The procedure for cell transplantation by intramyocardial injection was similar to 
that used in our previous studies143.  Briefly, 30 min after reperfusion, 2 ×105 human 
cardiac SSEA-3pos linneg,  an equivalent number of control cells (human dermal 
fibroblasts obtained from ATCC), or an equivalent volume of vehicle were injected 
intramyocardially using a 30-gauge needle. A total of four injections (10 µl each) were 
made in the peri-infarct region in a circular pattern, at the border between infarcted and 
non-infarcted myocardium. Mice were then allowed to recover for 39 days until 
euthanasia and tissue collection. 
Echocardiographic studies  
Murine echocardiographic images were obtained with a Vevo 2100 high 
frequency, high resolution (30 micron) digital imaging ultrasound system (VisualSonics, 
Inc.) as previously described.20 Serial echocardiograms were obtained at baseline (4 days 
prior to coronary occlusion/reperfusion and cell transplantation), 5 days after cell 
transplantation, and 35 days after cell transplantation (4 days prior to hemodynamic 
studies and euthanasia). All studies were performed under isoflurane anesthesia. Using a 
rectal temperature probe, body temperature was carefully maintained between 36.7 and 
37.3 ˚C throughout the study. Digital images were analyzed off-line by blinded observers 
using the Vevo 2100 workstation software. At least three measurements were taken and 
averaged for each parameter. Standard echocardiographic parameters were derived from 
the two-dimensional, M-mode, and Doppler images, as in our previous studies.20 
Speckle-tracking echocardiographic (STE) analysis was performed with the STE 
software, which utilizes semi-automated border tracking (VisualSonics, Inc.), as detailed 




Hemodynamic studies were performed 39 days after cell or vehicle treatment, just 
before euthanasia, using the ARIA-1 system and Millar catheter as described.141, 143 
Briefly, mice were anesthetized with isoflurane and rectal temperature kept between 36.7 
and 37.3 ˚C. A 1.0 French Millar catheter was inserted into the LV via the right carotid 
artery.  Inferior vena cava occlusion was performed with external compression to produce 
variably loaded beats for determination of the end-systolic PV relation (ESPVR) and 
other derived constructs of LV performance. As in the case of the echocardiographic 
studies, all hemodynamic data analyses were performed off-line by investigators blinded 
to treatment group. 
Cardiac tissue fixation and morphometric analysis 
At the conclusion of the in vivo study, the mouse heart was arrested in diastole by 
an intravenous  injection of 0.15 ml CdCl2 (100 mM), excised, and perfused retrogradely 
at 70–80 mmHg (LVEDP = 8 mmHg) with heparinized PBS followed by 10% neutral 
buffered formalin solution for 15 min. The heart was then sectioned into three slices from 
apex to base, fixed in formalin for 24 h, and subjected to tissue processing and paraffin 
embedding. Paraffin-embedded LV blocks were sectioned at a thickness of 4 µm for 
histochemistry and immunohistochemistry. Morphometric parameters, including LV 
cavity area, total LV area, risk region area, scar area, LV wall thickness, and infarct 
expansion index were measured in sections stained with Masson’s Trichrome as 
previously described.143 In each mouse heart, 4 – 5 slides were stained and analyzed. 
From apex to base, the average distance between two stained slides was 120 - 150 um. 
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Images were analyzed using NIH Image J (1.42v) and measurements from the various 
slices per heart averaged. 
Immunohistochemistry of murine cardiac specimens 
Formalin-fixed, paraffin-embedded, 4 µm-thick heart sections were 
deparaffinized in xylene and rehydrated gradually in a series of ethanol followed by 
antigen retrieval procedure. After incubation with blocking solution, persistence of 
transplanted human stem cells was determined by human nuclear antigen (HNA) 
(Millipore) immunofluorescent staining and confocal microscopy. The fate of 
transplanted cells was assessed by staining with specific antibodies against the myocyte 
marker cardiac troponin I (cTnI) (Santa Cruz), endothelial cell marker isolectin IB4 (Life 
Technologies), and smooth muscle cell marker α-smooth muscle actin (α-SMA) (Santa 
Cruz). Proliferation of transplanted cells was evaluated by immunofluorescent staining of 
nuclei for BrdU using a rat monoclonal antibody (Santa Cruz). In all of the 
immunofluorescent staining procedures, secondary antibodies conjugated with the 
appropriate fluorochromes (Jackson ImmunoResearch) were used. The concentration of 
primary and secondary antibodies corresponded to that indicated by the manufacturers. 
Immunohistochemical signals were acquired by confocal microscopy and quantitatively 
analyzed by Image J (1.42q, NIH). In each heart, HNA+ nuclei, double positive cells 
(HNA+/cTnI+, HNA+/IB4+, and HNA+/α-SMA+), triple positive cells 
(HNA+/cTnI+/BrdU+, HNA+/IB4+/BrdU+, and HNA+/α-SMA+/BrdU+), and total nuclei 
were counted in 25 confocal images acquired from the infarcted area (10), two border 





 Student’s t-test, one-way ANOVA, or two-way repeated measures ANOVA, as 
appropriate, was employed for comparisons of qPCR analyses as well as 
echocardiographic, hemodynamic, and immunohistochemical studies of murine hearts.  
All data are reported as means ± SEM.  
Results 
Localization of SSEA-3pos linneg cells in human right atrial tissue 
 Localization of human SSEA-3pos linneg cardiac cells was accomplished by 
immunohistochemical staining of formalin fixed, paraffin embedded, human right atrial 
tissue samples.  Immunolabeling was performed not only for localization but also for 
immunophenotypic characterization of the cells in situ with antibodies specific for c-kit 
(CD117), CD34, CD45, SSEA-3, and SSEA-4.    SSEA-3pos linneg cardiac cells were 
observed to be most highly prevalent within the subepicardium with a decreasing gradient 
to the compact myocardium where they were mainly visualized as single or doubly 
grouped cells within the interstitial space between myocytes (Fig. 16A and  Fig. 17A-C). 
SSEA-3pos linneg cells appropriately co-expressed SSEA-4 (Fig. 16B-D). In situ, SSEA-
3pos linneg cells were largely c-kit negative (Fig 16E-F); however, in very rare cases, 
overlapping expression of c-kit [i.e. SSEA-3pos SSEA-4pos c-kitpos cells] was also 
observed (Fig. 17D-G).  SSEA-3 expression did not overlap with mature myocytes, 




Figure 16. Cells expressing the embryonic stem cell-associate antigen SSEA-3 are 
present in the human heart and lack hematopoietic lineage markers (linneg). A. 
Transmission confocal microscopic image of human right atrial myocardium with 
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immunolabeling of SSEA-3 (green) and SSEA-4 (red). SSEA-3pos cells (green) are 
located in the cardiac interstitium between striated myocytes. Scale bar is 50um. B-D. 
Immunolabeling of SSEA-3 (green), SSEA-4 (red), and DAPI nuclear counterstain 
demonstrate that SSEA-3pos linneg cells appropriately co-express SSEA-4 (merged image). 
E. SSEA-3pos linneg cells (green) in the white box (enlarged in panel F) lack c-kit 
expression.  Scale bar is 50um. F. A c-kitpos cell is shown in close proximity to the 
SSEA-3pos linneg cells; this suggests that SSEA-3pos linneg cells are distinct from 
previously described populations of cardiac progenitors. G-I. The prevalence of SSEA-
3pos linneg cells in human right atrial myocardium was quantified by flow cytometric 
analysis after total enzymatic digestion of right atrial samples and was normalized to 
milligrams of right atrial tissue from which the cells originated.  G. An average of 
1.13±0.27 x 105 nucleated cells were analyzed per human right atrial sample (n=12) after 
complete enzymatic digestion. H. SSEA-3pos linneg cells accounted for 1.3±0.19% of total 
nucleated cells obtained from right atrial samples. I. The prevalence of SSEA-3pos linneg 




Figure 17. SSEA-3pos cardiac cells are located within the subepicardium and 
myocardial interstitium predominantly as solitary cells, and a subpopulation of 
SSEA-3 positive cells express c-kit, likely representing an intermediate phenotype of 
cardiac progenitors. A-C. Shown (top) are three confocal microscopy images of solitary 
SSEA-3pos cardiac cells (green) within formalin fixed adult human right atrial tissue 
specimens from separate patients. D. This confocal microscopic image demonstrates 
higher prevalence of SSEA-3pos cells within the subepicardium.   The SSEA-3pos cells 
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within the compact myocardium were observed as single cells within the interstitium as 
shown in images A-C.  SSEA-3pos (green) c-kitneg (red) cells are highlighted by arrows 
and c-kitpos SSEA-3neg cells by arrowheads (scale is 20um). Notably, a cell expressing 
both SSEA-3 and c-kit can be seen within the white box.  E. An enlarged image of the 
white box in image D shows the intermediate phenotype of SSEA-3 and c-kit positivity 
(scale is 10um).  F. Another example of an SSEA3pos c-kitpos cell within the white box. 
SSEA-3pos c-kitneg cells are indicated by arrows and a c-kitpos SSEA-3neg cell marked by 
the arrowhead (scale is 20um). G. A group of SSEA-3 expressing cells (arrowhead) 
within the myocardial interstitium between striated myofibrils is shown within the white 
box.  These cells co-express SSEA-4 as shown on the right with fluorophore separated 
images expanded from the white box.  One of the cells was observed to also express c-kit 
(arrow) in addition to SSEA-3 and SSEA-4. Scale bar is 10um. H. Flow cytometric based 
quantitation of cells obtained from freshly digested right atrial tissue samples 
demonstrated that cardiac SSEA-3pos linneg cells displayed partial overlap with SSEA-3 
expression (69.2±3.4%, n=10) validating the in vivo observation shown in images D-G. I. 
Immediately after enzymatic digestion, 7.18±1.78% of SSEA-3pos linneg cells co-




Prevalence of SSEA-3pos linneg cells in human right atrial tissue in situ 
The prevalence of SSEA-3pos linneg cells was quantified by immunolabeling of 
cardiac cells obtained after total enzymatic digestion of human right atrial tissue samples 
with antibodies specific to SSEA-3, CD34, and CD45. An average of 1.13±0.27 x 105 
nucleated cells were analyzed per human right atrial sample (n=12). SSEA-3pos linneg cells 
accounted for 1.3±0.19% of total nucleated cells obtained from right atrial samples after 
robust enzymatic digestion. The prevalence of SSEA-3pos linneg cells was 5.8±1.7 cells 
per milligram of right atrial tissue (Fig. 16G-I).   
Quantification of overlapping c-kitpos and SSEA-3pos linneg populations in situ 
Quantification of c-kitpos and SSEA-3pos populations was performed by 
immunolabeling and flow cytometric analysis (excluding CD34pos/45pos cells) after 
complete enzymatic digestion of right atrial tissue samples (n=10).  C-kitpos linneg cardiac 
cells demonstrated a high degree of overlap with SSEA-3 expression (69.2±3.41%).  
However, SSEA-3pos linneg cells demonstrated much less overlap with c-kit co-
expression: only 7.18±1.78% of SSEA-3pos linneg cells showed co-expression of c-kit 
(Fig. 17H-I) as assessed by flow cytometric analysis immediately after total enzymatic 
digestion.  
SSEA-3 immunoselection confers enrichment for markers associated with stemness 
and early cardiac commitment 
 After enzymatic digestion of right atrial tissue and primary expansion of tissue 
culture plate adherent cardiac cells, passage 1 cells were immunolabeled with antibodies 
specific to SSEA-3 and c-kit.  To validate the utility of SSEA-3 as a surrogate stemness 
associated cell surface molecular target by which cardiac precursors may be selected for 
115 
 
and isolated, SSEA-3pos linneg cells were FACS sorted for qPCR comparison with 
unsorted cardiac cells to determine if selection of cells expressing SSEA-3 results in 
enriched expression of the pluripotency associated markers OCT4 and NANOG as well 
as early and late cardiac markers NKX2.5 and GATA4 and MEF2C, respectively.  SSEA-
3pos linneg cardiac cells demonstrated higher expression of OCT4 (62.5±26.33 fold, 
P<0.05) and NANOG (89.7±42.6, P<0.05) as well as the early cardiac marker NKX2.5 
(137.3±75.3, P<0.05) (n=5), albeit at relatively low levels compared with the internal 
control (GAPDH or β2-microglobulin). There was no enrichment of GATA4 or MEF2C 
transcript expression in SSEA-3 expressing cells (Fig. 3) compared with unsorted cardiac 
cells.  All SSEA-3pos linneg cardiac cells at passage 1 lacked expression of the 
hematopoietic markers CD34 and CD45 (data not shown) and showed adherence to 
plastic culture plates, indicating that these cells are not hematopoietic progenitors (which 





Figure 18. SSEA-3 immunoselection: Enrichment of pluripotency associated 
markers, cardiac mesodermal markers, isolation and expansion. A. A representative 
FACS sorting plot of SSEA-3pos linneg cardiac cells at passage 2 is shown with sorting 
gate R4 (center panel) established with respect to isotype control (left panel) for false 
positivity <1%. In this patient, SSEA-3pos linneg cells were 2% of the total in vitro 
expanded cell population that were FACS sorted for qPCR-based comparison. 
Comparison of SSEA-3pos linneg FACS sorted cells to the unsorted population by qPCR 
demonstrated enriched relative expression of OCT-4 (62.5±26.33 fold, P<0.05), NANOG 
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(89.7±42.6, P<0.05), and NKX2.5 (137.3±75.3, P<0.05), n=5. B. Flow cytometric 
analysis of resultant magnetically sorted SSEA-3pos linneg cardiac cells is shown with 
gates established by isotype control <1% false positivity in P7 (left panel).  
Immunomagnetically sorted SSEA-3pos cells were 94% positive for SSEA-3 after MACS 
sorting in this particular patient. A representative light microscopic image of SSEA-3pos 
linneg cardiac cells is shown in the right panel (10x magnification). C. Confocal images of 
SSEA-3pos linneg cells (green) are shown in the left (10 um scale) and center (100 um 
scale). SSEA-3pos linneg cells at passage 2-3 demonstrated an average doubling time of 
26.5±2.11 h (n=9 patients).   D. Immunomagnetically selected SSEA-3pos linneg cardiac 
cells were assessed by flow cytometric analysis at the end of passage 2 for SSEA-3 
positivity.  A mean SSEA-3 positivity of 81.4±2.34% was achieved demonstrating 
reproducibility of isolation and in vitro expansion (n=32). E. Doubling times of 
immunomagnetically selected SSEA-3pos linneg cells calculated during passage 2-3 




Validation of clinically relevant methods of SSEA-3pos linneg cell isolation and 
expansion 
SSEA-3pos linneg cells could be sorted and enriched with high efficiency.  A 
representative flow cytometric plot of MACS enriched SSEA-3pos linneg cells as well as 
phase contrast and confocal microscopic immunocytochemical images of freshly MACS 
sorted SSEA-3pos linneg cardiac cells prior to passage 2 in vitro expansion are shown (Fig. 
18). In vitro expansion of SSEA-3pos linneg cells yielded approximately 3-5 x 106 cells at 
the end of passage 2 (demonstrating an average SSEA-3 positivity of 81.4±2.34%, n=32) 
which were able to be expanded exponentially to 30-50 x 106 cells by the end of passage 
3 for potential therapeutic utilization. The doubling time of SSEA-3pos linneg cells at 
passage 2-3 averaged 26.5±2.11 h (n=9) (Fig. 18). 
To validate the MACS based sorting methodology, a similar comparison of 
immuno-magnetically (MACS) selected SSEA-3pos linneg cardiac cells with the negatively 
sorted fraction was performed via qPCR (Fig. 4).  MACS selection of cells expressing 
SSEA-3 demonstrated consistent enrichment of cells expressing higher levels of NANOG 
(30.7±5.63 fold), OCT4 (8.48±2.01), MIXL1 (45.4±6.6), NKX2.5 (14.8±3.73), and 
TERT (48.2±13.3), P<0.05 (Fig 4A).  NANOG was detected by immunostaining with 
nuclear localization in some SSEA-3pos cells (Fig. 4D).  KDR and GATA6 exhibited a 
trend toward enrichment; however this was not statistically significant. Although there 
was no significant difference in the expression of TBX5, TBX18, TBX20, or GATA4 
transcripts between SSEA-3pos and SSEAneg cells, qPCR cycle times revealed relatively 
high expression of TBX18, TBX20, and GATA4 in both populations (data not shown).  
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TBX5 was detectable by qPCR, but lowly expressed in both SSEA3pos and SSEA3neg 






Figure 19. Characterization of in vitro expanded SSEA-3pos linneg.  A. qPCR of 
immunomagnetically selected SSEA-3pos cardiac cells demonstrated similar patterns of 
enrichment for pluripotency associated markers NANOG (30.6±5.63) and OCT4 
(8.48±2.01), early cardiac mesodermal markers MIXL1 (45.4±6.60) and NKX2.5 
(14.8±3.73), and telomerase reverse transcriptase, TERT (48.15±13.3), P<0.05. B.  Flow 
cytometric analyses of in vitro expanded SSEA-3pos linneg cells isolated from 6 human 
121 
 
right atrial tissue samples consistently demonstrated a mesenchymal phenotype with near 
complete positivity for CD105 (98.8±0.43%), CD73 (98.8±0.74%), CD29 (99.5±0.11%), 
CD44 (99.5±0.31%), CD166 (96.7±3.90%), and HLA class 1 (97.4±1.18%) and 
heterogeneity of CD90 (59.6±4.77%) expression.  SSEA-3pos linneg cells lacked 
expression of hematopoietic markers CD34 and CD45 (0.53±0.09%), c-kit (0.28±0.06%), 
CD31 (0.48±0.13%) and HLA class 2 (0.35±0.11%).  Heterogeneity of KDR expression 
was observed (7.0±0.56%). C. As SSEA-3 expression was observed to decrease over 
time and with passaging, qPCR performed after SSEA-3 re-enrichment by 
immunoselection of cells retaining SSEA-3 expression at advanced passage (passage 9) 
showed continued enrichment of pluripotency associated markers NANOG (89.6±23.3) 
and OCT4 (44.6±14.0) as well the early cardiac marker NKX2.5 (57.6±19.0) compared 
with that of the SSEA-3 negative fraction.  GATA4 and GATA6 expression was not 





Immunophenotypic analyses of SSEA-3pos linneg cells 
SSEA-3pos linneg cardiac cells at passage 2 were analyzed by flow cytometry for 
co-expression of mesenchymal, endothelial, and hematopoietic lineage markers (Fig. 20).  
SSEA-3pos linneg cells demonstrated a predominantly mesenchymal phenotype, with near 
complete positivity for CD105 (98.8±0.43%), CD73 (98.8±0.74%), CD29 (99.5±0.11%), 
CD44 (99.5±0.31%), CD166 (96.7±3.90%), and human leukocyte antigen (HLA) class 1 
(97.4±1.18%) and heterogeneity for CD90 (59.6±4.77%) and KDR (7.0±0.56%) 
expression (Fig. 20).  SSEA-3pos linneg cells lacked the endothelial marker CD31 
(0.48±0.13%), hematopoietic lineage markers CD34 and CD45 (0.53±0.09%), and HLA 
class 2 (0.35±0.11%).  Despite showing positivity for SSEA-3 and SSEA-4, in vitro 
expanded cells did not express the tumor related antigen (TRA)-1-60 or TRA-1-81 that 
are commonly observed, in addition to SSEAs, in iPSCs and ESCs.207  Although 
overlapping c-kit expression was observed in situ (vide supra) (~ 8% of SSEA-3pos linneg 
cardiac cells immediately after total enzymatic digestion, n=10) (Fig. 17), analyses at 
passage 2 after in vitro expansion did not demonstrate any appreciable c-kit expression 
(0.28±0.06%), indicating that c-kit expression is transient, that SSEA-3pos c-kitpos cells do 
not expand in the present culture conditions, or that SSEA-3pos c-kitpos cells proliferate at 




Figure 20. Immunophenotype of in vitro expanded SSEA-3pos linneg CPCs. Flow 
cytometric detection of progenitor (SSEA3, C-KIT), endothelial (CD31, KDR), 
mesenchymal (CD29, CD44, CD73, CD90, CD105, CD166), human leukocyte (HLA-1, 




TBX18 has been observed to be expressed in proepicardial progenitors110, 
although recent evidence suggests that it is not completely confined to this compartment 
within the fetal or mature heart.111 Therefore, our observation of TBX18 mRNA 
expression within SSEA-3pos linneg cells (vide supra) cannot conclusively link these cells 
to a particular cardiac progenitor lineage from fetal development.  In contrast, Wilms 
tumor gene 1 (WT-1), a marker with significant overlapping expression with TBX18, has 
been utilized to exclusively define and track distinct proepicardial lineage derivatives, 
epicardial derived cells (EPDCs), and epicardial epithelial to mesenchymal transition 
(EMT) during cardiac development.84, 104, 105  WT-1 has also been demonstrated to be 
expressed in response to myocardial injury within epicardial cells, essentially reactivating 
a fetal gene program for cardiac repair after infarction.197, 210, 211  We observed WT-1 
expression within in vitro expanded SSEA-3pos linneg cells.  Immunostaining showed 
primarily nuclear with some cytoplasmic localization of WT-1 (Fig. 19E). PCR analysis 
of SSEA-3pos linneg cells confirmed transcript expression of WT-1 (Fig. 21).  Observation 
of WT-1 expression may suggest SSEA-3pos linneg cells are originally of proepicardial 
origin.   Incidentally, SSEA-3pos linneg cells also demonstrated robust expression of IGF-




Figure 21.  Validation of PCR products.  Shown are representative gels validating 
target sizes of PCR products ensuring specificity and appropriate target size with negative 




SSEA-3pos linneg cells are clonogenic and display multipotent differentiation potential 
toward myocytes, smooth muscle, and endothelial cells 
 Freshly sorted human cardiac SSEA-3pos linneg cells were plated at low density in 
suspension culture for assessment of their ability to expand and form spheres 
spontaneously, which would indirectly imply clonogenic ability.  SSEA-3pos linneg cells 
formed spheres in suspension culture resembling previously described cardiospheres (Fig. 
22A).213  Spheres were allowed to expand; replating of spheres on normal tissue culture 
plates resulted in expansion of cells contained within the spheres, confirming that the 
spheres consisted of viable cells.  The cell surface immunophenotype of SSEA-3pos linneg 
cells that were expanded in suspension and allowed to form spheres did not differ, after 
replating and in vitro expansion, from those expanded in adherent monolayer conditions. 
The immunophenotype of SSEA-3pos linneg cells was similar to that of cardiosphere-
derived cells214, 215 as well as c-kit sorted cardiac cells140 with respect to cell surface CD 
marker expression (Fig. 20). 
Terasaki plates were seeded by limiting dilution with one cell per well to evaluate 
clonogenicity.  Singly seeded SSEA-3pos linneg cells formed colonies at an average 
frequency of 21.16±3.8%, n=8. Representative single cell cloning progression is shown 
in Figure 22B. 
 SSEA-3pos linneg cells at passage 2 were placed in directed differentiation 
conditions to induce myocyte, smooth muscle, and endothelial differentiation.  
Immunocytochemistry of cells placed in myogenic differentiation conditions 
demonstrated upregulation of the sarcomeric proteins alpha-myosin heavy chain (α-
MHC) and α-sarcomeric actin after 35 days (Fig. 22C).  Connexin 43 expression was 
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visualized at sites of cell-cell contact, indicating functional gap junction formation 
between adjacent cells (Fig. 22B).  However, the staining pattern of sarcomeric proteins 
did not yield mature, striated sarcomeric structures, indicating incomplete differentiation.  
Robust smooth muscle differentiation was observed, with marked upregulation of smooth 
muscle actin and upregulation of smooth muscle myosin heavy chain (Fig. 22E).  After 
differentiation, cell morphology was consistent with mature appearing smooth muscle 
cells.  Endothelial differentiation conditions resulted in marked upregulation of CD31 
(PECAM) by immunostaining and confocal microscopy (Fig. 22F) and flow cytometric 
analysis (Fig. 22G), with changes in morphology resembling typical endothelial cells.  
Flow cytometric analysis of SSEA-3pos linneg cells during endothelial differentiation 
demonstrated upregulation of CD31 at day 4 and appropriate down regulation of SSEA-3.  
By day 10, >75% of cells had become CD31 positive with complete loss of SSEA-3 
expression.  Endothelial differentiated cells formed tubes when seeded in matrigel, 






Figure 22. SSEA-3pos linneg cells display clonogenic and multipotent differentiation 
capacities expressing mature cardiac markers of myocytes, smooth muscle, and 
endothelial cells under directed in vitro differentiation conditions. A. SSEA-3pos linneg 
cardiac cells demonstrated the ability to form expanded spheres in suspension when 
seeded at very low density, indicative of clonogenic ability.  Attached SSEA-3pos linneg 
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cells are shown after immunoselection (top left panel). Multicellular spheres formed and 
expanded after low density seeding in suspension culture (center panels).  These 
multicellular spheres contained viable cells as evidenced by the attachment and 
expansion of cells when seeded into normal tissue culture plates (right image). B. True 
clonogenic ability was evaluated by singly seeded SSEA-3pos linneg cardiac cells in 
Terasaki plates shown (left) with enlarged image expanded in the box. Clonogenic 
expansion is seen in the center panel with four cells having originated from a single 
SSEA-3pos linneg, ultimately giving rise to a colony (right panel). Singly seeded SSEA-3pos 
linneg cells from different human patients formed clonal colonies in Terasaki plates at an 
average frequency of 21.16±3.8% as shown in the bar graph on the right (n=8). Values in 
graphs are represented as mean±SEM. C. Immunocytochemistry showing expression of 
alpha-myosin heavy chain (green) and alpha-sarcomeric actin (red) after directed 
myogenic differentiation.  Nuclei were counterstained with DAPI (blue). D. 
Differentiated SSEA-3pos linneg cells formed gap junctions with adjacent cells highlighted 
by connexin 43 (red) expression (arrow) and alpha-tubulin (green). E. SSEA-3pos linneg 
cells robustly formed smooth muscle like cells illustrated by smooth muscle actin (green) 
expression.  F.  Expression of CD31 (magenta) is shown resulting from 10 days of 
endothelial directed differentiation conditions. G. The time course of endothelial 
differentiation is illustrated over 10 days for SSEA-3 positive cells [81% SSEA-3pos/<1% 
CD31pos] at day 0 with respect to isotype control.  CD31 was upregulated at day 4 and 
robustly at day 10 [78% CD31pos] with loss of SSEA-3 during differentiation (<1% at day 
10).  Functional capacity with endothelial tube formation of CD31pos differentiated 
SSEA-3pos linneg CPCs is shown in the right panel. Scale bars are 50um. 
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SSEA-3pos linneg cells induce cardiac repair and functional recovery after 
ischemia/reperfusion injury 
 The effect of SSEA-3pos linneg cardiac cell administration on LV remodeling after 
myocardial infarction was investigated by morphometric analysis of Masson’s trichrome 
stained sections (Fig. 23A).  Although the LV risk region was similar across all groups 
(Fig. 23B), mice that received SSEA-3pos linneg cells exhibited a statistically significant 
increase in viable myocardium relative to vehicle (Fig. 23A&B).  Further, as there were 
no significant differences in mean anterior wall (infarcted wall) thickness across groups, 
LV expansion indices were markedly reduced in SSEA-3pos linneg cell-treated animals 
relative to vehicle (Fig. 23C).  
 The effect of SSEA-3pos linneg cardiac cell therapy on ventricular volume and 
function after myocardial infarction was investigated by echocardiographic analyses and 
Millar methodology.  Significantly reduced left ventricular end-diastolic (Fig. 24A) and 
end-systolic (Fig. 24B) volumes were observed in the SSEA-3pos linneg cell treatment 
group compared to vehicle treated controls. Accordingly, measurements of left 
ventricular ejection fraction were significantly higher in the SSEA-3pos linneg cell 
treatment group compared to controls by both single plane B-mode (44.4±2.8% vs. 
29.8±2.8%) and Simpson’s biplane (44.8±2.5% vs. 31.3±1.8%) methods of assessment. 
In the setting of comparable body weights and heart rates between the treatment and 
control group (data not shown), high ejection fraction in the cell treatment group 







Figure 23. Left ventricular morphometric analyses. Vehicle (black), cell control 
(white), and SSEA-3pos linneg cells (grey) groups. Serial echocardiographic studies were 
performed under isoflurane anesthesia at baseline (4 days prior to surgery) and 5 and 35 
days after myocardial infarction. Data are mean ± SEM. A. Mason’s trichome staining 
shows increased viable myocardium and decreased scar size in a representative cross-
section of the left ventricle from a cell treated heart vs. that of control. B. Viable tissue 
was significantly larger with similar size of risk region in the cell treated hearts over 




Figure 24. Left ventricular volumetric comparison.  Left ventricular end diastolic and 
end systolic volumes were assessed by Simpson’s method echocardiography comparing 
SSEA-3pos linneg cells (EA-CPC) treatment and vehicle control groups at baseline, 5 days 
and 35 days after I/R injury.  A. The average left ventricular end diastolic volume was 
significantly smaller in the SSEA-3pos linneg cells treatment group (67.0ul) vs that of the 
control (79.9ul) indicating less adverse LV remodeling and less decompensatory LV 
dilatation in the SSEA-3pos linneg cells treatment group.  B. Similarly, end systolic 
volumes were significantly smaller in the SSEA-3pos linneg cells treatment group than 
control group.  Human SSEA-3pos linneg cells abrogate LV dilatation and adverse 
remodeling after ischemia/reperfusion injury that is known to lead to heart failure as well 
as promote restoration of systolic function after ischemic injury. There was no difference 
between groups at baseline or at 5 days (p>0.05) indicating similar starting cohorts of 





Figure 25. Ejection Fraction.  Echocardiography (echo) was performed for left 
ventricular functional assessment in an immunocompromised murine model (SCID mice) 
of  ischemia/reperfusion (I/R) injury and subsequent human SSEA-3pos linneg cell 
intramyocardial administration.  Echo was performed at baseline prior to injury as well as 
5 days and 35 days post I/R with subsequent cell therapy by intramyocardial injection of 
200K human SSEA-3pos linneg cells or normal saline control in the border zones of the 
infarction area. A. Significant improvement in cardiac function was seen over 35 days in 
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the SSEA-3pos linneg cells treatment group (EA-CPCs) vs that of the control group 
(CTRL).  The control group had an average ejection fraction (EF) of 29.8% while the 
human SSEA-3pos linneg cell treated group saw significant functional improvement to 
44.4% (p<0.05) as measured in B Mode echocardiography. B. Ejection fraction assessed 
by Simpson’s method echocardiography showed similar a pattern of improvement in the 
SSEA-3pos linneg cell (EA-CPC) treatment with 44.8% EF vs. 31.3% EF in the control 
group.  There was no significant difference between groups at baseline or at 5 days by 
either measurement methodology indicating no difference in starting populations/cohorts 
of SCID mice and no difference in the extent of induced myocardial injury. 
Improvements observed at 35 days are solely due to the treatment with SSEA-





Figure 26.  Stroke work and cardiac output. A.Stroke work and B. cardiac output were 
measured by standard Millar methodology.  These functional parameters were observed 
to be significantly increased/improved as a result of human SSEA-3pos linneg cells 






In summary, we have provided for the first time direct evidence of the existence 
of multipotent SSEA-3pos linneg cardiac progenitor cells, which are not a culture derived 
phenotype but exist in the native human neonatal and adult myocardium.  We have 
shown for the first time that these SSEA-3pos linneg cardiac progenitor cells can be isolated 
and expanded in vitro for the ultimate purpose of use in inducing repair of damaged 
and/or poorly functioning myocardium.  To confirm that these cells truly have a 
phenotype expected of progenitor cells, we have performed the most extensive 
characterization ever attempted in any adult progenitor cell population.  We validated not 
only the expression of markers such as pluripotent stem cell associated markers of oct4 
and nanog but also telomerase, which allows these cells to preserve their progenitor 
phenotype and avoid excessive shortening of their telomeres with repetitive cell 
proliferation in vitro.  Thusly, these cells retain a large proliferative reserve allowing 
sufficient numbers of cells for a therapeutic cell product of SSEA-3pos linneg cells to be 
generated.  We have shown these cells possess a cardiac predisposition as they have 
heterogeneous baseline expression of transcription factors showing early commitment to 
mature cardiac lineages of endothelial, smooth muscle, and cardiomyocytes.  
Furthermore, SSEA-3pos linneg cardiac progenitor cells up-regulate mature sarcomeric 
proteins of smooth muscle and myocytes as well as surface markers and functional 
characteristic of endothelial cells in in vitro myogenic and endothelial differentiation 
conditions respectively.  In other words, SSEA-3pos linneg cardiac progenitor cells have 
cardiac multilineage potential.  This pattern of gene expression and organ specific 
predisposition is unique to progenitor cells isolated from the human heart and in contrast 
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to any ability of other non-embryonic or neonatal non-cardiac stem cell populations (i.e. 
MSCs from various tissues other than heart, HSCs, non-cardiac local tissue progenitors) 
whose native function is not to contribute directly to lineages of the heart or directly to its 
homeostasis.  We have shown that our methods of isolation and expansion are 
reproducible, and that SSEA-3pos linneg cardiac progenitor cells populations from different 
patients have very similar progenitor gene expression patterns.  We have utilized 
clinically relevant methodologies that show exactly the characteristics and capabilities of 
SSEA-3pos linneg cardiac progenitor cells that would be used in a clinically relevant 
therapeutic application.  With these methodologies we have verified within a model of 
ischemically damaged myocardium that administration of SSEA-3pos linneg cardiac 
progenitor cells can induce cardiac repair and abrogate adverse myocardial remodeling 
that leads to functional decompensation.  Again, to our knowledge, a comprehensive 
report of the discovery, isolation, characterization, and evidence of therapeutic utility of 
this kind, related to adult progenitor cells, has never been put forth.  The clinically 
applicable methodology demonstrated above enables rapid bench to bedside applications.   
Future directions 
 Presently, analyses of the SSEA-3pos linneg  cardiac progenitor cell treated hearts 
are underway to evaluate whether donor cells engrafted into recipient hearts. Moreover, 
did donor cells differentiate into mature cardiac phenotypes representing true 
regeneration? If this is not observed, it would indicate primarily a paracrine action of 
these cells on the recipient myocardium by which preservation and recovery of LV 
function was observed compared to controls, similar to other cell types utilized for 
cardiac cell based therapies to date. Regardless of whether the SSEA-3pos linneg  cardiac 
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cells work by engrafting and differentiating into mature myocytes or via paracrine 
mechanisms, the discovery of this heretofore unknown cell population is an important 
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